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Abstract
Major depressive disorder is a common and devastating psychiatric disorder. While 
pharmacotherapy and psychotherapy can be effective, a significant proportion of pa-
tients remain treatment resistant. Traditional antidepressants need to be taken for sev-
eral weeks or months before the therapeutic effects become evident. For treatment-re-
sistant patients, electroconvulsive therapy (ECT) is still the most effective treatment. 
Postictal slowing of electroencephalogram (EEG) activity has been associated with the 
therapeutic effects of ECT, but the mechanistic basis of this remains poorly studied. For 
decades this has encouraged researchers to investigate the antidepressant effects of iso-
flurane anesthesia with promising, but inconsistent, results. More recently, evidence of 
the rapid-acting antidepressant effects of subanesthetic doses of ketamine, an N-meth-
yl-D-aspartate receptor (NMDAR) antagonist and a dissociative anesthetic, has sparked 
a renewed interest in the development of novel antidepressant therapies. Another 
treatment to show positive results is nitrous oxide (N2O), a gaseous anesthetic with 
NMDAR antagonist properties. One of the proposed mechanisms of ketamine’s action 
is related to its ability to increase glutamatergic signaling, leading to further changes 
in synaptic potentiation and in the function of neuronal networks. These changes have 
been suggested to involve the actions of brain-derived neurotrophic factor (BDNF) sig-
naling via its receptor TrkB. Downstream of TrkB, the inhibition of glycogen synthase 
kinase 3β (GSK3β), the induction of mammalian target of rapamycin (mTOR) mediat-
ed protein synthesis, and the consolidation of synaptic changes have been implicated 
in ketamine´s actions. 
 The first aim of this study is to investigate the molecular changes induced by iso-
flurane anesthesia in the adult mouse hippocampus using phosphoproteomics in the 
absence of a priori information. We find that brief isoflurane anesthesia induces 318 
phosphorylation changes in a total of 237 proteins. While confirming the phosphoryla-
tion alterations on selected proteins, we also discover that various anesthetics, includ-
ing urethane and ketamine, regulate these targets in a similar manner. In the second 
part, we investigate the effects of N2O on molecular signatures implicated in ketamine’s 
action. Findings reveal that N2O produces cortical excitation, followed by the rebound 
emergence of slow EEG activity following gas cessation, which coincide with the phos-
phorylation of TrkB, GSK3β and p70S6k (a kinase downstream of mTor). Moreover, 
we demonstrate that these pathways become regulated during the postictal period af-
ter flurothyl-induced seizures or during slow EEG activity induced by hypnotic agent 
medetomidine. Notably, medetomidine is not effective in the learned helplessness test. 
Finally, we investigate the dose-dependent changes induced by ketamine in TrkB sig-
naling. An acute administration of sedative-anesthetic doses of ketamine, accompanied 
by increases in slow EEG activity, is found to increase the phosphorylation of the in-
vestigated pathways. These changes appear independent of ketamine’s metabolite hy-
droxynorketamine, an agent shown to have antidepressant-like behavioral effects in 
rodents. 
 In conclusion, our results provide novel evidence of a specific brain state charac-
terized by slow EEG oscillations and the activation of molecular pathways implicated 
in rapid-acting antidepressant actions. These findings encourage the investigation of 
cortical excitation and the subsequent homeostatic increase of slow EEG oscillations as 
a fundamental basis of rapid-acting antidepressant treatments.
IV
Tiivistelmä
Masennus on yleinen psykiatrinen sairaus, joka aiheuttaa mittavaa inhimillistä kärsi-
mystä ja merkittäviä yhteiskunnallisia kustannuksia. Masennusta hoidetaan farmakote-
rapialla, mutta moni potilaista ei saa merkittävää hyötyä lääkkeistä useiden viikkojen tai 
kuukausienkaan käytön jälkeen. Näille hoitoresistenteille masennuspotilaille psykiatri-
nen sähköhoito on yhä tehokkain hoitomuoto. Yhdeksi sähköhoidon tehoa ennustavak-
si tekijäksi on esitetty kouristuksen jälkeisen aivojen hidasaaltotoiminnan lisääntymistä 
aivosähkökäyrässä. Ajatus kannusti tutkijoita selvittämään isofluraanilla aikaansaadun 
anestesian masennuslääkevaikutuksia jo vuosikymmeniä sitten, mutta tulokset jäivät 
epäselviksi. Tuoreemmissa tutkimuksissa on puolestaan toistettavasti havaittu N-me-
tyyli-D-aspartaatti (NMDA) -reseptoreja salpaavan ketamiinin nopea masennusoireita 
lievittävä vaikutus. Hiljattain kliinisessä tutkimuksessa on havaittu myös NMDA-resep-
toreja salpaavan typpioksiduulin (N2O) masennusoireita nopeasti lievittävä vaikutus. 
Isofluraanin ja typpioksiduulin vaikutusten taustalla olevat neurobiologiset mekanis-
mit ovat kuitenkin yhä pääosin tuntemattomia. Ketamiinin vaikutusmekanismiksi on 
sen sijaan esitetty glutamatergisen hermovälityksen ja aivokuoren ärtyvyyden lisäänty-
mistä, jonka on ajateltu johtavan muutoksiin synapsien ja hermosolujen toiminnassa. 
Näiden vaikutusten on esitetty aiheutuvan aivoperäisen hermokasvutekijän (BDNF) 
kohteena toimivan TrkB-reseptorin aktivaatiosta ja sitä seuraavista muutoksista glyko-
geenisyntaasikinaasi 3β:n toiminnassa ja rapamysiinin mekaanisen kohteen (mTOR) 
ohjaamassa proteiinisynteesissä.
 Ensimmäisessä tutkimuksessa keskityimme selvittämään isofluraanianestesian aihe-
uttamia molekulaarisia muutoksia hiiren hippokampuksessa, jonka tutkimisessa hyö-
dynsimme fosfoproteomiikkaa. Havaitsimme 318 fosforylaatiomuutosta 237 eri proteii-
nissa. Vahvistaessamme havaittuja muutoksia valikoiduissa proteiineissa havaitsimme 
monien eri anesteettien, kuten uretaanin ja ketamiinin, aiheuttavan samankaltaisia 
muutoksia. Tutkimuksen toisessa osassa selvitimme N2O:n vaikutuksia ketamiinin sää-
telemiin solusignalointimekanismeihin hiiren etuaivokuorella. Ilokaasualtistuksen aika-
na havaittiin hermoston aktiivisuuteen liitettyjen merkkiaineiden lisääntymistä. Annos-
telun päätyttyä aivosähkökäyrässä havaittiin voimistunutta hidasaaltotoimintaa, jonka 
aikana kerätyissä aivonäytteissä havaittiin TrkB-välitteisen signaloinnin lisääntyneen. 
TrkB-signalointi lisääntyi myös näytteissä, jotka kerättiin flurotyylin aiheuttamien kou-
ristuksien tai hidasaaltotoimintaa suoraan lisäävän medetomidiinin annostelun jälkeen. 
Medetomidiini ei kuitenkaan aiheuttanut masennuslääkkeille tyypillisiä käyttäytymisen 
muutoksia ns. opittu avuttomuus -mallissa. Lopuksi selvitimme ketamiinin annosriip-
puvaisia vaikutuksia TrkB-signalointiin hiiressä. Anesteettiset ketamiiniannokset lisäsi-
vät aivosähkökäyrän hidasaaltotoimintaa, jonka aikana kerätyissä näytteissä havaittiin 
TrkB-signalointipolun aktivoituneen. Ketamiinin aiheuttamat muutokset näihin solu-
signalointimekanismeihin eivät näyttäisi olevan riippuvaisia sen metaboliatuotteesta 
hydroksinorketamiinista, jolla on esitetty olevan masennuslääkevaikutuksia koe-eläi-
miin. 
 Tutkimustuloksemme viittaavat siihen, että hidasoskillaatioilla ja ketamiinin vaiku-
tuksiin liitetyillä solusignalointimuutoksilla olisi yhteys. Lisäksi tulokset kannustavat 
selvittämään, ovatko aivokuoren ärtyvyys ja sitä seuraava hidasaaltotoiminnan lisäänty-
minen nopeavaikutteisten masennuslääkkeiden yhteinen ominaisuus.
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DEpRESSION is a disabling condition suffered by almost 350 million people worldwide (Smith, 2014). It produces immense individual suffering and 
is responsible for a large part of the total burden of nervous system disorders. 
Monoaminergic antidepressant drugs and psychotherapy constitute the main 
line of therapy against depression. The beneficial effects of traditional antide-
pressant effects typically become evident after weeks or months of continu-
ous medication, but a significant number of patients do not respond to these 
treatments at all (Fava, 2003; Trivedi et al., 2008). For these treatment-resistant 
patients, interventions like electroconvulsive therapy (ECT) are often effective 
(Fink, 2001). However the use of ECT is limited by available resources, cogni-
tive side-effects (Nuninga et al., 2018), and disrepute among the general public 
(Sienaert, 2016).
The discovery of the rapid-acting antidepressant effects of ketamine (Ber-
man et al., 2000), an N-methyl-D-aspartate receptor (NMDAR) antagonist and 
a dissociative anesthetic, has brought renewed interest in the development of 
novel antidepressant drugs with a rapid onset of action. Ketamine produces a 
rapid and robust amelioration of depressive symptoms in many patients, with 
the effects often beginning within hours of a single intravenous infusion (Wal-
ter et al., 2014). The antidepressant effects of ketamine, however, only last from 
a couple of days to a few weeks. Moreover, ketamine is a drug of abuse (Dillon 
et al., 2003), which has undeniably limited its widespread clinical use. 
Intriguingly, other anesthetic drugs have also displayed rapid-acting anti-
depressant properties in some clinical trials (Langer et al., 1995; Mickey et al., 
2018; Nagele et al., 2015). These trials have reported similar treatment effects 
to ECT without some of the cognitive side effects. While several different mo-
lecular mechanisms and cellular signaling pathways have been implicated in 
the rapid-acting antidepressant effects of ketamine, the neurobiological basis 
of these effects remains obscure. Thus, further understanding of the molecular 
mechanisms behind the rapid antidepressant action of ECT and ketamine, as 
well as other anesthetics, will provide tools for both refining current practices 
and for the discovery of novel somatic and pharmacological treatments. 
The literature review in this thesis briefly describes the history of antide-
pressants and associated theories of depression to provide a foundation for 
discussing the latest scientific knowledge regarding rapid-acting antidepres-
sants. The experimental findings provide novel insights into the neuropharma-
cological mechanisms of anesthetic drugs and their putative associations with 
rapid-acting antidepressant effects. 
2
2 REVIEW OF THE LITERATURE
2.1 Major depressive disorder
MAjOR depressive disorder (MDD) is the most common mood disorder in the world (Smith, 2014), causing immense individual suffering and 
impairment of social and occupational functioning (Whiteford et al., 2013). 
It is a significant risk factor for suicide (Chesney et al., 2014) and one of the 
biggest contributors to the economic burden caused by diseases (Olesen et al., 
2012). The estimated lifetime prevalence of MDD is close to 15% (Bromet et 
al., 2011), and the World Health Organization has predicted that MDD will 
become the most burdensome disease in the world within this century (Mous-
savi et al., 2007). 
Major depressive disorder is a complex pathology with many levels of dif-
ferent symptoms and multiple possible contributing etiological factors, such 
as stress (Kendler et al., 1999), inflammation (Vogelzangs et al., 2012), cog-
nitive and emotional factors (Joormann & Siemer, 2011), genetic predisposi-
tion (Dunn et al., 2015), and developmental processes (Whittle et al., 2014). 
Moreover, environmental factors such as maltreatment during childhood have 
been strongly associated with a substantially increased risk of depression in 
adulthood (Li et al., 2016). Depression shares features with normal emotional 
responses of sadness and grief, but in MDD these feelings become dispropor-
tionate to their cause and are not relieved despite the alleviation of external 
causes (Belmaker & Agam, 2008). Major depressive disorder is characterized 
by at least one depressive episode lasting for a duration of at least two weeks 
(Otte et al., 2016). During a depressive episode, distinctive changes in mood 
and loss of interest and/or pleasure in daily activities take place along with al-
terations in cognitive functioning, which may manifest as a diminished ability 
to think or concentrate. The heterogeneity of the disorder is further demon-
strated by varying and sometimes opposing symptoms, such as weight loss or 
weight gain and insomnia or hypersomnia (van Loo et al., 2012). Important-
ly, sleep disturbances are very commonly associated with depressive disorders 
(Riemann et al., 2001).
Major depressive disorder is most prevalent in adults aged 18 to 64 years, 
with a median age of onset in the 20s (Kessler et al., 2003, 2012). Depressive 
episodes, however, may appear at almost any age. Childhood depression is 
rarely diagnosed partly due to a lack of research and proper criteria. Typically, 
the first diagnosis is made during adolescence or early adulthood (Egger & 
Angold, 2006). When compared to adolescents (13-17 years) or older adults 
(65+ years), adults (18-64 years) are twice as likely to be diagnosed with MDD 
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(Kessler et al., 2003, 2012). In addition, women are much more likely to be di-
agnosed with MDD than men regardless of the age group in question.
While major advances in understanding the complex neurobiological 
mechanisms behind MDD have been made, no complete mechanisms have 
been established that would explain all aspects of the disease. This is exem-
plified by the fact that the clinical diagnosis of depression and the treatments 
in use are still lacking objective biomarkers (Jentsch et al., 2015). Among the 
functional and structural alterations that have been associated with MDD are 
reductions in hippocampal volumes (Kempton, 2011), changes in the activity 
or connectivity of neuronal networks (Menon, 2011), alterations in inflamma-
tory activity (Nusslock & Miller, 2016), and the dysregulation of brain metab-
olism and sleep (Breslau et al., 1996; Germain et al., 2004).
Several pharmacological and non-pharmacological treatment options ex-
ist for MDD. The most widely used pharmacotherapy is per os medication with 
selective serotonin/noradrenalin reuptake inhibitors (e.g. SSRIs and SNRIs), 
but only 35-50% of patients receive benefits from these drugs (Murrough & 
Charney, 2012; Trivedi et al., 2006, 2008). A significant portion of patients do 
not exhibit a favorable response to treatment with one or more antidepressants, 
and are categorized as having treatment-resistant depression (Fava, 2003). For 
the patients that do respond to antidepressant treatment, a significant delay 
exists between the initiation of pharmacotherapy and full remission. Moreover, 
chronically depressed patients may only begin to respond after 8 to 10 weeks of 
drug treatment (Keller et al., 1998). Notably, the improvement achieved with 
traditional antidepressants has been suggested to be minimal in milder forms 
of depression (Fournier et al., 2010). 
Besides traditional pharmacotherapy, psychotherapy is also common-
ly used in treating MDD. Psychotherapy is generally estimated to be equally 
as effective as pharmacotherapy in treating MDD (Amick et al., 2015), and 
non-pharmacological therapies may be particularly helpful in preventing 
recurring depression (Clarke et al., 2015). Any direct comparison between 
non-pharmacological and pharmacological treatments is difficult due to meth-
odological differences. Psychotherapy is rarely used alone in treating severe de-
pression, but it may be combined with pharmacotherapy (Depression. Current 
Care Guidelines, 2016). On the other hand, psychological interventions may 
hold particular promise in treating subclinical depression and preventing the 
onset of major depressive disorder (van Zoonen et al., 2014). 
Different neurobiological hypotheses of depression have been proposed 
over the years, including impaired monoamine neurotransmission, altered ac-
tivity of the hypothalamic-pituitary-adrenal (HPA) axis, neuroinflammation 
(Nusslock & Miller, 2016), impaired neurotrophic signaling and plasticity 
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(Duman et al., 1997), and impaired neuronal network wiring (Castrén, 2013). 
However, these hypotheses are not mutually exclusive, and each may contrib-
ute to different aspects of the disease. As will be elaborated upon in the fol-
lowing chapters, many of these hypotheses have been generated along with 
the accumulation of understanding of the mechanisms of action of traditional 
antidepressant drugs or through serendipitous clinical observations.
2.1.1 A brief history of antidepressants
Since ancient times, psychiatric ailments have been treated with natural rem-
edies. Some of these phytotherapeutics, like Hypericum perforatum (St. John’s 
Wort) (Istikoglou et al., 2010), are still in use and have been shown to produce 
some antidepressant effects in modern clinical trials (Linde et al., 2005). The 
plant Papaver somniferum, a source of opium and morphine, has a history of 
medical use that likely dates back to ancient times, as witnessed by archeo-
logical findings of Minoan artefacts (Askitopoulou et al., 2002). More docu-
mented uses of opium for melancholia are from the 18th century (Weber & 
Emrich, 1988). Among one of the earlier somatic treatments for depression is 
sleep deprivation, which essentially consists of depriving depressed patients of 
sleep. The first written accounts of sleep deprivation as a putative treatment for 
melancholia date back to the first half of the 19th century and were the work 
of psychiatrist jOhANN ChRISTIAN AuguST hEINROTh (Steinberg & Hegerl, 
2014). Clinical experiments of using sleep deprivation were carried out in later 
decades (Schilgen & Tölle, 1980). Sleep deprivation therapy is still in use in 
some countries.
The accounts of experimental seizure-provoking treatments for psychi-
atric disorders date back to the 1930s (Kalinowsky, 1986). Like all previous 
therapies, these methods were discovered not by understanding the etiology 
of the disease, but by the clinical observation of psychiatric patients. Insulin 
coma therapy, championed by MANfRED SAkEl, was practiced from 1933 un-
til the late 1950s (Crammer, 2000; Jones, 2000; Shorter, 2009). In this form of 
therapy, psychiatric patients were put into a hypoglycemic coma using high 
doses of insulin. After waking up from the coma, patients were often agitated 
and sometimes experienced generalized convulsions (Kral & Laponte, 1956). 
During the 1930s, another new therapeutical concept was developed based on 
the idea of seizures having therapeutic effects. This new treatment was coined 
convulsive therapy and it was introduced mainly by the Hungarian psychiatrist 
lADISlAS vON MEDuNA, who experimentally induced seizures using camphor 
and pentylenetetrazol in psychiatric patients (Fink, 2001). Meduna’s idea of the 
therapeutic effects of convulsive therapy was based on the observations that 
spontaneous seizures, such as those occurring after barbiturate withdrawal, 
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often resulted in the temporary loss of psychotic symptoms in schizophrenic 
patients (Kalinowsky, 1986). The results from using electricity to produce sim-
ilar convulsions in animals were first reported in an English journal by luCIO 
BINI (1938), the student of ugO CERlETTI, and the first patient trials soon 
followed (Aruta, 2011; Cerletti & Bini, 2018). The positive observations from 
early trials led to the development of ECT as an easier, less expensive, and safer 
alternative to chemical seizure therapies. In general, convulsive therapies were 
first used to treat schizophrenic patients, but they were later found out to be 
very effective for depression as well (Kalinowsky, 1986). After the establish-
ment of ECT, chemical seizure therapies continued to be experimented with 
in the 1950s. Among novel agents used for inducing seizures was the volatile 
convulsant flurothyl (Esquibel et al., 1957), which demonstrated effects similar 
to ECT (Fink, 2014). Insulin coma therapy, however, was withdrawn in the 
late 1950s and has been discredited by some as a passing medical fad without 
proper scientific basis (Jones, 2000).
At the end of the 19th century pAul ERlICh, who synthesized the arse-
nic medicine arsphenamine for syphilis, first articulated the idea that chem-
ical substances might have specific actions on disease processes (Winau et 
al., 2004). He described these new pharmacotherapies as “magic bullets” that 
could act specifically on infections without affecting rest of the body. Follow-
ing these lines, the views on how psychiatric drugs worked also changed in the 
1950s (Moncrieff, 2008). In the previously dominant drug-centered perspec-
tive, psychiatric drugs were inducers of abnormal states such as sedation or 
stimulation, and these states were considered useful in some manifestations of 
psychiatric conditions. These views gave way to the new disease-centered view, 
in which drugs were seen to treat the underlying causes of the disease, and thus 
classes of drugs like antipsychotics and antidepressants were coined. 
The development of the first so-called antidepressant drugs began in the 
1950s, when the available pharmaceuticals for treating psychiatric disorders 
were few (Moncrieff, 2008). Medications against depression were mostly lim-
ited to amphetamine, which had been marketed for the treatment of mild 
depression since 1935 (Guttmann & Sargant, 1937), and opiates, which were 
used historically for many psychiatric conditions (Weber & Emrich, 1988). A 
completely new perspective on antidepressant development was fueled by the 
serendipitous discovery of the antidepressant effects of the anti-tuberculosis 
agent isoniazid (Pletscher, 1991). A drug with a very similar chemical structure, 
iproniazid, became the first pharmaceutical to be marketed solely for treating 
depression. It was thought to do so by inhibiting the action of the enzyme 
monoamine oxidase (MAO), responsible for the degradation of monoamines. 
This discovery was soon followed by a wave of novel monoamine oxidase in-
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hibitors and tricyclic antidepressants, the first of the tricyclic drugs being imip-
ramine. Along with the new antidepressants, the discovery of the antipsychotic 
drug chlorpromazine has been credited with having led the way to a new era 
in the treatment of mental disorders. Furthermore, these new drugs played an 
important role in replacing rudimentary neurosurgical procedures and also led 
to a decline in the use of convulsive therapies (Kalinowsky, 1986). 
The introduction of the first line of psychiatric medications, the advanc-
ing understanding of the function of synapses, and the discovery of the spec-
trophotofluorimeter triggered the development of neuropharmacology in the 
mid-1950s (Ban, 2001). During the following decades, dozens of new antide-
pressants were developed following the basic pharmacological principle called 
the monoamine theory of depression (Hirschfeld, 2000). The scientific advances 
in receptor binding assays allowed further sophistication in drug development 
(Ban, 2001). The advent of modern antidepressant drugs became most evident 
with the work that led to the discovery of fluoxetine in the 1970s (Perez-Cabal-
lero et al., 2014). As a selective serotonin reuptake inhibitor (SSRI), fluoxetine 
had a much tolerable pharmacodynamic profile than the previous generation 
of antidepressants and proved to be a massive commercial success. The efficacy 
of fluoxetine suggested that selective regulation of serotonergic neurotransmis-
sion had antidepressant effects, and soon after, several new drugs appeared on 
the market with a similar mechanism of action. In the 1980s, the identification 
and separation of receptor subtypes along with genetic technology paved the 
way for more tailor-made antipsychotics and antidepressants (Ban, 2001). To-
day, molecules with slightly different receptor profiles and milder side effects 
are continuously being developed, but the efficacy of antidepressant drugs has 
not improved since the discovery of tricyclic antidepressants (Figure 1) (Cip-
riani et al., 2018; Undurraga & Baldessarini, 2017).
While the monoaminergic hypothesis of depression dominated the field 
for decades, some other lines of investigation were also carried out. In the 
1960s, some clinical reports described the anxiolytic and antidepressant ef-
fects of gamma hydroxybutyrate, now known to act on both GABAB (gam-
ma-aminobutyric acid B) and GHB (gamma hydroxybutyric acid) receptors 
(Bosch et al., 2012). Early work with ketamine and psychedelic drugs hinted 
of their potential in psychiatric use, but the research was more qualitative than 
quantitative in nature (Clark, 1975; Clark, 1977; Khorramzadeh & Lotfy, 1973; 
Wolfson & Wolfson, 2014), and was often performed in incoherent ways. In the 
1980s and 1990s, pilot clinical experiments sought to examine the idea that the 
postictal silencing and burst-suppressing electroencephalogram (EEG) activ-
ity, also seen after ECT seizures, might produce antidepressant effects instead 
the seizure itself. These EEG changes seen after ECT, essentially short periods 
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of high-amplitude low-frequency bursts of activity, can be achieved with deep 
isoflurane anesthesia. This pharmacologically induced EEG burst-suppression 
produced by isoflurane was found to elicit antidepressant responses in patients 
suffering from major depression (Langer et al., 1985; Carl et al., 1988; Engel-
hardt et al., 1993; Langer et al., 1995). While the results from these trials were 
promising, showing treatment effects comparable to ECT with fewer cognitive 
side-effects, some groups reported limited or no beneficial effects from volatile 
anesthetics (Greenberg et al., 1987; García-Toro et al., 2001). Due to conflict-
ing results and the lack of animal research, these studies did not gain much 
attention until recently, when Weeks et al. (2013) replicated some of Langer’s 
initial work by demonstrating the antidepressant effects of isoflurane in a small 
open-label trial.
The rapid advances in understanding the nervous system along with new 
developments in the basic tools of molecular biology opened new perspec-
tives in examining antidepressant effects in preclinical research. The discovery 
of nerve growth factor (NGF) in the early 1950s by RITA lEvI-MONTAlCINI 
and vIkTOR hAMBuRgER (Levi-Montalcini & Hamburger, 1951) was followed 
decades later by the discovery of brain-derived neurotrophic factor (BDNF) 
(Barde et al., 1982). These neurotrophins were found to have essential roles 
in mediating the development of the nervous system (Davies, 1994; Huang 
& Reichardt, 2001), but also in mediating neuronal plasticity in the adult 
Figure 1. Overview of antidepressant developments. MAOI, monoamine oxidase 
inhibitor; TCA, tricyclic antidepressant; SSRI, serotonin reuptake inhibitor; SNRI, se-
rotonin and noradrenaline reuptake inhibitor; NRI, noradrenaline reuptake inhibitor; 
NDRI, noradrenaline and dopamine reuptake inhibitor; NASSA, noradrenergic and 
specific serotonergic antidepressant; MT, melatonin receptor.
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brain (Poo, 2001; Thoenen, 1995). Moreover, the discovery of neurotrophins 
paved the way for the seminal work done by RONAlD DuMAN and colleagues, 
who demonstrated that monoaminergic antidepressants and electroconvul-
sive shock (ECS; a rodent model of ECT) produced gradual increases in the 
synthesis of BDNF in the hippocampus and cortex of rodents (Nibuya et al., 
1995). Taken together, these discoveries led to the presentation of a molecular 
and cellular theory of depression, with the regulation of neurotrophic factors 
and neuronal plasticity by antidepressants being one of the key mechanisms 
of action (Duman et al., 1997). Since then, some scientists have suggested that 
traditional antidepressants act as “plasticity enhancers” capable of reactivating 
sensitive period-like plasticity and brought up questions about the importance 
of psychotherapy in conjunction with antidepressants (Castrén, 2013; Castrén 
& Hen, 2013).
The work of phIl SkOlNICk and colleagues linked antidepressant-like be-
havioral outcomes in animal models to NMDARs (Trullas & Skolnick, 1990). 
In another study, a link between the chronic administration of traditional anti-
depressants and alterations in NMDAR subunit messenger RNA (mRNA) ex-
pression was discovered (Boyer et al., 1998). Following these findings, a major 
breakthrough in depression research came with a clinical study that demon-
strated the rapid-acting antidepressant effects of subanesthetic ketamine (Ber-
man et al., 2000). Ketamine was not only found to provide rapid amelioration 
of depressive symptoms, but to have efficacy in treatment-resistant and suicidal 
MDD patients. These findings marked a shift in approaching the pharmacolog-
ical basis of antidepressant effects from monoaminergic neurotransmission to 
glutamatergic neurotransmission. Importantly, the fact that ketamine, also a 
drug of abuse, could be administered in small dosages that elicited only minor 
psychoactive effects was promising for the development of non-psychoactive 
novel molecules. In the following decades, a myriad of drug candidates tar-
geting glutamatergic neurotransmission emerged, but they have had relatively 
little clinical success so far. The preclinical studies of ketamine have, however, 
strengthened the association of neurotrophic signaling, synaptogenesis, and 
neurogenesis with the mediation of antidepressant effects (Duman & Aghaja-
nian, 2012; Ma et al., 2017).
Evidence of other putative rapid-acting antidepressants besides ketamine 
have emerged in the recent years. One small pilot study recently demonstrated 
the promising rapid-acting effects of the anesthetic gas nitrous oxide (N2O) in 
the treatment of MDD (Nagele et al., 2015). Even more recently, psychedelic 
drugs like psilocybin, targeting the 5-hydroxytryptamine receptor 2A (5-HT2A), 
have regained attention regarding their role in the treatment of psychiatric 
disorders. The most recent evidence regarding psilocybin comes from a pilot 
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clinical trial where the drug was found to produce rapid and long-lasting an-
tidepressant effects in a small sample of MDD patients (Carhart-Harris et al., 
2016). Along with these findings and the re-introduction of psychedelic drugs 
to modern neuroscience, old perspectives on the importance of the psycholog-
ical experience in a therapeutic context have been brought back into modern 
discussion (Carhart-Harris et al., 2018).
2.1.2 Major hypotheses of depression and antidepressant action
The monoamine hypothesis of depression has unarguably had the largest im-
pact on the research of antidepressant drugs and depression to date. This hy-
pothesis was formulated following several different converging observations 
regarding the role of monoamines and especially serotonin in brain function 
and drug action. Intriguingly, one of the key drivers for this progress was the 
surge in scientific research conducted with the then recently discovered lyser-
gic acid diethylamide (LSD), which was found to block the effects of serotonin 
on peripheral receptors and to cause strong hallucinogenic effects in humans 
(Woolley & Shaw, 1954). However, before the role of serotonin in the brain was 
discovered, the pharmacological properties of serotonin were mostly associated 
with its ability to cause smooth muscle contractions and subsequent vasocon-
striction – hence the term serotonin, or “serum tonic”.  vITTORIO ERSpAMER 
extracted a compound from enterochromaffin cells and named it enteramine in 
1937 (Ersparmer & Viallu, 1937). Later, it was found to be the same compound 
as serotonin (Erspamer & Asero, 1952), which was separately discovered by 
MAuRICE RAppORT and colleagues (Rapport et al., 1948) and characterized 
as 5-hydroxytryptamine (5-HT) (Rapport, 1949). Just a few years after the dis-
covery of serotonin, Woolley and Shaw (1954) first speculated that the mental 
aberrations produced by LSD were the result of the substance interfering with 
the function of serotonin in the brain. While vivid debates on the role of sero-
tonin in the central nervous system were launched (“The Role of Serotonin in 
the Central Nervous System,” 1956), the notion of chemical transmission in the 
brain prevailed, and monoaminergic neurotransmitters began to be considered 
crucial for controlling brain activity (Gaddum, 1963).
Findings related to the drug reserpine, an antihypertensive drug extracted 
from the plant Rauwolfia serpentina, formed another important link between 
noradrenaline, serotonin, and depression (Pletscher, 1991). Reserpine was 
found to inhibit vesicular monoamine transporters (VMAT) responsible for 
the transport of intracellular monoamine transmitters into presynaptic vesicles 
and to deplete the brain of monoamines in large doses (Brodie et al., 1955), 
precipitating depressive symptoms in some individuals (Muller et al., 1955). 
Both serotonin and reserpine were found to act as sedatives in mice and could 
10
potentiate the action of other hypnotic drugs. These effects could be counter-
acted by pretreating the animals with LSD (Shore et al., 1955). Noradrenaline 
could not be ruled out as a mediator either, since the precursor to noradrena-
line, dihydroxyphenylalanine, has been effective in reversing reserpine induced 
effects in animals (Carlsson et al., 1957).
Another line of evidence came along with the discovery of the euphor-
ic and stimulating effects of the tuberculosis drugs isoniazid and iproniazid 
(Crane, 1956). Iproniazid was discovered to act as an inhibitor of monoamine 
oxidases (MAOI), which are enzymes responsible for the oxidative deamina-
tion, or inactivation, of free intracellular monoamine neurotransmitters. Es-
sentially, pre-administration of iproniazid was found to reverse the action of 
reserpine by sparing cytosolic monoamines from inactivation and turning 
reserpine’s sedative effects into stimulation (Pletscher, 1991). These findings 
were well in line with the notion that increasing the synaptic concentrations of 
monoamines led to the relief of depressive symptoms, and these observations 
were one of the key factors in the development of the monoamine hypothesis 
(Bunney & Davis, 1965; Hirschfeld, 2000; Schildkraut, 1965). In particular, the 
monoamine hypothesis proposed that depression is a disease manifested by 
reduced levels of noradrenaline, dopamine, and/or serotonin in the brain, and 
that this could be counteracted by the inhibition of the enzyme responsible for 
breaking down these substances. 
The discovery of the antidepressant effects of imipramine, the first of many 
antidepressant drugs with a tricyclic structure, did not at first fit into the ini-
tial monoamine theory since it only marginally affected MAO enzymes (Plet-
scher, 1991). Imipramine was originally developed as a sedative anxiolytic for 
use in agitated psychotic patients. Its use as an anxiolytic was unsuccessful 
because it had the tendency to provoke manic effects, but patients with de-
pression showed remarkable stimulation and relief (Kuhn, 1958). After the 
serendipitous discovery of its antidepressant potential, imipramine was found 
to inhibit the reuptake of noradrenaline and serotonin, with lower doses act-
ing as stimulant and higher doses producing sedation in animals (Maxwell & 
Palmer, 1961). A number of drugs were produced based on the tricyclic struc-
ture following imipramine, and these had potent effects on both serotonin and 
noradrenaline (Hillhouse & Porter, 2015; Owens et al., 1997). Tricyclic antide-
pressants, however, possess a number of off-target effects to muscarinic, adren-
ergic, and histaminergic receptors that lead to a wide variety of unwanted side 
effects, such as sedation, dry mouth, blurred vision, and hypotension (Gill-
man, 2007). In the 1960s, evidence from a postmortem study indicated that 
the levels of serotonin in the hindbrain were decreased in depressed patients 
that had conducted suicide (Shaw et al., 1968), and other studies indicated the 
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mood-promoting effects of the serotonin precursor tryptophan in conjunction 
with MAOIs (Coppen et al., 1963; Pollin et al., 1961). These and other studies 
further advanced understanding of the role of serotonin in mediating mood. 
To combat both the side effects of tricyclic antidepressants and the prima-
ry target of rational drug design, the development of more pharmacologically 
specific drugs began. Indeed, drugs such as fluoxetine, sertraline, and citalo-
pram addressed some issues of safety and tolerability by being more selective 
to serotonin reuptake inhibition without potent off-target effects (Owens et 
al., 1997). Following the success of SSRIs, drugs that selectively target nor-
adrenaline reuptake inhibition (NRIs), like reboxetine, or drugs that target 
serotonin and noradrenaline reuptake (SNRIs), like duloxetine, were also been 
developed. In addition, a group of drugs labeled as atypical antidepressants 
have primary targets other than the regulation of serotonin and/or noradren-
aline. This class consists of a wide variety of drugs with targets varying from 
noradrenaline and dopamine reuptake inhibition (NDRIs, e.g. bupropion) 
to noradrenergic and specific serotonergic antidepressants (NaSSAs, e.g. mir-
tazapine) and melatonin receptor agonists (e.g. agomelatine). Despite the tri-
umph of more selective antidepressants, some tricyclic antidepressants are still 
in active clinical use and their antidepressant effects are comparable to SSRIs 
(Cipriani et al., 2018; Undurraga & Baldessarini, 2017).
The monoamine hypothesis continued to gather strong support until the 
last few decades, when contradicting hypotheses and evidence surfaced. For 
example, more recent evidence indicates that monoamine depletion in healthy 
subjects does not provoke episodes of depression (Salomon et al., 1997), and 
that the depletion of monoamines or tryptophan levels does not increase de-
pressive symptoms in MDD patients without medication (Berman et al., 2002). 
In a meta-analysis of monoamine depletion studies, decreased mood was 
demonstrated only in patients with a family history of MDD and in patients 
who are not currently on medication and have MDD in remission (Ruhé et al., 
2007). This meta-analysis also concluded that these depletion studies fail to 
demonstrate a causal relationship between monoamine depletion and MDD. It 
is, however, possible, that different paradigms of depletion and prolonged de-
pletion periods could have more pronounced effects in provoking depression.
Another line of evidence against the monoamine hypothesis of depres-
sion comes from the acute pharmacological action of antidepressant drugs. 
Since most of these drugs elicit their effects on synaptic concentrations of 
monoamines within hours of drug administration, antidepressant effects 
could be expected to be almost immediate. However, the antidepressant ef-
fects become evident only after weeks or months of continuous treatment. For 
example, in a trial by Glassman and Platman (1969), treatment with MAOI 
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and tryptophan had an onset of 7 to 21 days, though the treatment is expected 
to produce an immediate increase of serotonin in most brain areas. This delay 
in antidepressant effects is a critical concern in clinical practice, where pa-
tient compliance is important and suicidal symptoms are sometimes present. 
Moreover, it is well known that the adverse effects of antidepressants often 
manifest rapidly after treatment initiation, which further indicates immediate 
effects on monoamines. Another clinically relevant problem is that many pa-
tients do not respond to any traditional antidepressant treatments, but remain 
pharmaco-resistant. Were depression a disease only dictated by insufficient 
monoamine activity in the sense of the traditional hypothesis, relief would be 
achieved by increasing monoamines with the many means available to clini-
cians today.
The growing body of evidence against the monoamine hypothesis has 
encouraged researchers to look for new neurobiological clues that could ex-
plain antidepressant effects beyond monoamines. Refinements to the original 
hypothesis have also been made, such as the addition of new mechanistic 
layers including the regulation of monoamine receptor dynamics (Charney et 
al., 1981; Zemlan & Garver, 1990). A hypothesis born out of these new ideas 
proposed that the regulation of neurotransmitter release by serotonin autore-
ceptors is crucial in explaining the delayed onset of action of antidepressant 
drugs (Blier & de Montigny, 1994; Stahl, 1998). These receptors are located 
not only on the postsynaptic terminal, but also in the cell body, as in the case 
of 5-HT1A receptors (Hannon & Hoyer, 2008; Sprouse & Aghajanian, 1987; 
Weissmann-Nanopoulos et al., 1985), or in the vicinity of presynaptic axon 
terminals,  as in the case of 5-HT1D receptors (Hannon & Hoyer, 2008; Hoyer 
& Middlemiss, 1989; Waeber et al., 1990), where they have regulatory roles 
in controlling neuronal activity and transmitter release. The stimulation of 
5-HT1A autoreceptors located in the raphe nucleus, where most serotonergic 
neuronal cell bodies reside, decreases the firing of these neurons and thus re-
duces the amount of 5-HT released from neuronal projections (Rutter et al., 
1995; Sprouse & Aghajanian, 1987), a phenomenon known to happen during 
physiological activity and acutely after SSRI treatment (Bel & Artigas, 1992; 
Chaput et al., 1986; Invernizzi et al., 1992). Chronic treatment with SSRIs, 
however, results in the desensitization of 5-HT1A receptors, which leads to the 
disinhibition of neuronal activity and increased serotonergic neurotransmis-
sion. Indeed, increased levels of extracellular 5-HT have been observed in 
some chronic studies (Bel & Artigas, 1993; Rutter et al., 1994), but not in all 
(Hjorth & Auerbach, 1994). Following this idea, it has been suggested that the 
continuous presence of SSRIs might be important to maintain high enough 
extracellular 5-HT levels for the therapeutic effects (Invernizzi et al., 1996).
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Intriguingly, many antidepressant drugs with atypical pharmacological pro-
files that do not easily fit the confines of even the refined monoamine hypoth-
esis have also been discovered. Some of these drugs, such as tianeptine and 
mianserin, date back to the 1960s, while others have been developed more re-
cently, like mirtazapine and agomelatine. For example, tianeptine does not 
inhibit serotonergic, dopaminergic, or noradrenergic transporters or receptors, 
but may in fact increase serotonin uptake (Kasper & McEwen, 2008; Mennini 
et al., 1987). Interestingly, tianeptine’s main action has been proposed to be 
mediated through μ-opioid receptors (MOR) (Gassaway et al., 2014; Samuels 
et al., 2017). Moreover, many antidepressants are prescribed today for a vari-
ety of conditions ranging from obsessive compulsive disorder to social phobia 
and post-traumatic stress disorder (Schatzberg, 2000), which has prompted 
discussion on the validity of calling these drugs antidepressants (Lara & Souza, 
2001). Novel therapeutic approaches have been warranted, and the develop-
ment of new drugs based on old principles have been discouraged by some 
researchers (Agid et al., 2007).
Alternative views on the importance of monoamine transmission in the 
mechanism of action of antidepressants have also been expressed. For exam-
ple, Heninger et al. (1996) state that monoaminergic systems are more mod-
ulatory in nature and may interact with other systems to produce antidepres-
sant effects. They proposed that antidepressant effects may manifest through 
the modulation of different systems, for example, by affecting glutamatergic 
neurotransmitters and normalizing the function of the HPA axis, by altering 
neurotrophin signaling, or through effects on immune systems and various 
intracellular cascades. Indeed, many of these areas of research have gathered 
increasing attention in the last decades. Some researchers have also proposed 
the idea of serotonin playing a completely opposite role, so that serotonin 
transmission is in fact increased in depression (Andrews et al., 2015).
Abnormalities in the activity of the HPA axis have been proposed to play 
a key role in the etiology of depression (Ehlert et al., 2001; Gold & Chrousos, 
2002; Gold et al., 1988; Holsboer, 2000; Merali, 2004). Essentially, stress-caus-
ing stimuli lead to the activation of the autonomic sympathetic nervous system 
and the HPA axis. While the autonomic nervous system is responsible for the 
acute and rapid stimulation of adrenaline secretion by the adrenal glands, the 
HPA axis uses corticotropin releasing factor (CRF) as its first-line messenger 
(Chrousos & Gold, 1998). Corticotropin releasing factor is released from the 
paraventricular nucleus of the hypothalamus and further stimulates the release 
of adrenocorticotropic hormone (ACTH) from the pituitary, which results in 
the synthesis and release of the glucocorticoid hormone cortisol (corticosterone 
in rodents). Glucocorticoids serve several functions, from catabolic action to 
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the suppression of the immune system. Most importantly, glucocorticoids play 
a key role in the homeostatic regulation of stress responses. A study investigat-
ing the pituitary volume of treatment-naive pediatric patients found that MDD 
patients had significantly larger pituitary gland volumes than healthy controls. 
The biggest differences were observed in boys suffering from nonfamilial MDD 
(MacMaster et al., 2006)
While normal responses to stress, as regulated by the HPA axis, are typical-
ly adaptive and help an organism to cope with stress-inducing situations, exces-
sive and prolonged stress responses can have harmful effects. For example, ear-
ly life stress has been reported to cause changes in the ability of the HPA axis to 
respond to stress during adulthood and is associated with an increased risk of 
psychiatric disorders (Heim et al., 2008; Martins et al., 2011). In addition, the 
incidence of major depressive episodes is associated with more frequent stress-
ful life events (Hammen, 2005). During chronic stress, glucocorticoid levels 
are elevated, which can produce atrophic changes in the hippocampus. This is 
supported by findings that depression duration predicts hippocampal volume 
loss in otherwise healthy women (Sheline et al., 1999). Additional evidence 
has been found in studies detecting decreased neurogenesis, synaptogenesis, 
and dendritic spines in relation to stress (Egeland et al., 2015). Moreover, pa-
tients who suffer from Cushing’s syndrome, characterized by abnormally high 
levels of circulating cortisol, often show depressive symptoms and atrophic 
changes in the hippocampus (Starkman et al., 1992; Starkman & Schteingart, 
1981). However, not all patients display abnormalities in the HPA axis, while 
some types of depression are overrepresented when HPA changes are exam-
ined (Stetler & Miller, 2011). 
A systematic review looking at atypical and melancholic depressive sub-
types found that melancholic depression is especially associated with increased 
cortisol levels (Juruena et al., 2018). Elevated cortisol in depression may be 
caused by issues at different levels of regulation, including impairment of the 
negative feedback from glucocorticoid receptors (Boero et al., 2018), increased 
responsiveness of the adrenal glands to circulating ACTH, and the abnormal 
secretion of CRF. Taken together, these findings have encouraged investiga-
tors to seek potential targets of drug development. In animal studies, centrally 
administered CRF has been reported to reduce exploratory behavior in novel 
environments and to cause stress-induced freezing behavior, among other be-
havioral changes (Dunn & Berridge, 1990), while CRF antagonists have been 
found to reverse some of these outcomes (Heinrichs et al., 1995). Antagonists 
targeting glucocorticoid and CRF receptors have been developed and tested 
for treating depression and anxiety disorders among other uses, but such drugs 
have not yet entered the market. While some positive results have been report-
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ed with CRF1 antagonists attenuating stress responses in primates (Habib et 
al., 2000) and reducing the effects of chronic mild stress in behavioral para-
digms of mice when combined with fluoxetine (Ducottet et al., 2003), CRF 
antagonists have failed to produce antidepressant-like behavioral effects in rats 
tested with the forced swim test (FST) (Jutkiewicz et al., 2005). 
The  forced swim test is one of the most widely used behavioral models in 
the characterization of monoaminergic antidepressants, in which a rodent is 
placed in a beaker filled with water, unable to escape from the water and the 
confined space. The injection of an antidepressant drug prior to the testing typ-
ically results in an increased time spent actively swimming before settling for 
passive floating. This effect is typical to most monoaminergic antidepressants 
and has served as an excellent predictor of antidepressant potential in new 
drug candidates, since up to 90% of clinically effective antidepressants show 
significant results in the FST (Borsini & Meli, 1988). This test, however, may 
not be optimal for measuring putative antidepressants with novel mechanisms 
of action. Comprehensive clinical trials may be required to further assess the 
potential of CRF antagonists in depression.
The wide array of non-antidepressant applications of antidepressant drugs 
and the discovery of the regulation of neurotrophic factors by antidepressants 
formed the basis for the neurotrophin hypothesis of depression (Figure 2). 
This important hypothesis revolves around the idea of depression being the 
consequence of insufficient neurotrophic signaling, leading to impaired con-
nectivity and survival of neurons especially in brain areas important for mood 
regulation (Duman et al., 1997). This hypothesis is supported by the preclinical 
findings that stress and glucocorticoid injections could decrease the expression 
of BDNF and promote atrophy of hippocampal neurons (Smith et al., 1995), 
while chronic antidepressant treatment (Dwivedi et al., 2006), ECS (Nibuya et 
al., 1995), or exercise (Russo-Neustadt et al., 1999) could prevent this down-
regulation in rodents. Subsequently, neurotrophic factors and plasticity-relat-
ed signaling pathways became a major branch of depression research. 
Indeed, continuous antidepressant administration to rodents subjected 
to chronic stress can reduce immobility time in the FST and prevent the re-
duction of sucrose consumption in the sucrose preference test (Haenisch et 
al., 2009), which are thought to be markers of antidepressant-like action. The 
sucrose preference test measures the preference animals have for drinking a 
sweet sucrose solution compared to water. A decrease in preference is thought 
to be indicative for anhedonia. Furthermore, evidence linking BDNF to anti-
depressant-like behavioral responses in the learned helplessness (LH) model 
and FST in rats have been demonstrated in studies investigating direct infu-
sions of BDNF into the midbrain (Siuciak et al., 1997) and the dentate gyrus 
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of the hippocampus (Shirayama et al., 2002). Similar results have also been 
achieved using intracerebroventricular infusion in rats, from which the effects 
on FST were found to persist for six days after a single infusion (Hoshaw et 
al., 2005). In addition, reduced BDNF expression levels have been measured 
post mortem in the brains of suicide victims (Dwivedi et al., 2003) and serum 
levels of BDNF have been found to be lower in the serum of depressed patients 
(Molendijk et al., 2014). Increased BDNF expression in the hippocampus of 
depressed patients has been noted after antidepressant treatments (Chen et al., 
2001).
In addition to the neurotrophin hypothesis, the network hypothesis of de-
pression has also been discussed in the scientific literature. While the neu-
rotrophin hypothesis suggests that insufficient neurotrophic support under-
lies depression, the network hypothesis postulated that the amelioration of 
depression is the result of increased plasticity and consecutive adaptations 
in neuronal networks, and that this network wiring could be modified by in-
creasing neuroplasticity through antidepressant drugs and activity-dependent 
processes (Castrén, 2013). Most importantly, this hypothesis accounts for the 
delay in the onset of action of traditional antidepressant drugs and suggests 
that antidepressant treatments may be most effective when combined with 
Figure 2. Overview of some of the major hypotheses of depression. 
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psychotherapy. Since neuronal plasticity and the shaping of neuronal net-
works are activity-driven processes (Hensch, 2005), environmental guidance 
may play a key role (Castrén, 2013; Castrén & Hen, 2013). Indeed, this idea is 
supported by the ability of the antidepressant drug fluoxetine to reintroduce 
juvenile-type plasticity in the rat visual cortex and to facilitate recovery from 
developmental amblyopia (i.e. reduced vision in one eye due to closing of the 
eye during a sensitive period) (Vetencourt et al., 2008). Similar effects have 
been observed in mice using fear conditioning, where a combination of ex-
tinction training with fluoxetine produced a sustained loss of conditioned fear 
responses (Karpova et al., 2011). This suggests that similar phenomena might 
be occurring in mood-related circuitry. 
Built upon the foundations of the neurotrophin and network hypotheses 
of depression, a hypothesis called undirected susceptibility to change proposes 
that SSRI treatments do not enhance mood as such, but amplify the influ-
ence of external conditions on the depressed patients (Branchi, 2011). Sever-
al lines of preclinical and clinical studies have recently emerged that support 
such an idea. For example, mice subjected to chronic stress and treated with 
fluoxetine in an enriched condition improved their depression-like symptoms 
in behavioral tests, while stressful conditions led to worsening of behavioral 
responses (Alboni et al., 2017; Branchi et al., 2013). Moreover, citalopram has 
been suggested to produce antidepressant outcomes that are dependent on 
socioeconomic status (Viglione et al., 2019) and living conditions (Chiarotti 
et al., 2017). Further research is required to elucidate the complex interactions 
between SSRI treatment and environmental factors, and whether they are of 
significant clinical importance.
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2.2   Rapid-acting treatments of depression
ClINICAl DEpRESSION is likely to develop slowly, with functional alter-ations taking place long before major depressive episodes appear. While 
traditional antidepressants take time to ameliorate depressive symptoms, rap-
id-acting treatments of depression can be characterized by the rapid (within 
days) or almost immediate (within hours) relief of depressive symptoms after 
a single treatment. The question of how such alterations can develop so slowly 
yet be remedied so rapidly remains unanswered. Despite gaps in understand-
ing the mechanisms of action behind rapid-acting treatments of depression, 
two clinically effective treatments are in active use. These are electroconvulsive 
therapy and the intravenous administration of ketamine. Emerging evidence 
indicates that several other putative rapid-acting antidepressant treatments 
may also exist. In this chapter, clinical and preclinical research on rapid-acting 
antidepressant treatments that have demonstrated efficacy in clinical trials is 
reviewed from neuropharmacological and neurobiological perspectives.
2.2.1   Electroconvulsive therapy
The use of ECT as a psychiatric treatment began in the late 1930s (Bini, 1938; 
Cerletti & Bini, 2018). Electroconvulsive therapy is still in widespread use and 
remain one of the most effective and rapid treatments for MDD, in particular 
for pharmacoresistant depression. Many different treatment protocols exist, 
and they vary according to the disease being treated, since ECT is also widely 
used for the treatment of other disorders like mania (Small et al., 1985) and 
schizophrenia (El-Islam et al., 1970). The current form of ECT consists of a 
brief pulse of electrical stimulation under anesthesia, oxygenation, and contin-
uous monitoring. This makes modern ECT much safer and more effective than 
the historical treatments. The effectiveness of ECT in the treatment of depres-
sion has been well demonstrated, and shown to be superior to pharmacothera-
py (Giacobbe et al., 2018; Husain et al., 2004; UK ECT Review Group, 2003).
When compared to traditional pharmacotherapy, ECT produces a more 
rapid alleviation of depressive symptoms (Husain et al., 2004; Spaans et al., 
2015). Electroconvulsive therapy is most often delivered as a series of 6 to 12 
treatments, typically three times a week, and a reduction in depressive symp-
toms is typically seen in 2-4 weeks. It has been reported that over half of the 
patients treated with ECT received an initial response already within the  first 
week of treatment (Husain et al., 2004). Electroconvulsive therapy treatment 
also reduces suicidality to a greater degree than traditional pharmacotherapies 
(Kellner et al., 2005). From a clinical perspective, this relatively rapid action is 
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particularly important in severely depressed and suicidal patients. Systemat-
ic monitoring of treatment responses is important, especially since premature 
discontinuation can lead to relapse of depression.
While ECT is an effective treatment, it can also cause clinically significant 
adverse cognitive effects in some patients (Nuninga et al., 2018). These vary 
from mild memory problems to more severe (and rare) delirium. Research has 
demonstrated that cognitive functions do recover in the following months after 
the treatment, but concerns about the safety of ECT remain persistent. Obbels 
et al. (2018) demonstrated that no significant long-term cognitive side effects 
were visible six months post-ECT in any of the neuropsychological measure-
ments investigated in late-life depressed patients. Similar results were also ob-
tained by Nuninga et al. (2018), who reported acute negative cognitive effects, 
but also recovery after six months. Partly fueled by gruesome depictions of 
ECT in popular culture (Sienaert, 2016) and the misunderstanding that ECT 
severely damages the brain and cognition, many patients refrain from consid-
ering ECT as a treatment option. While studies on humans and nonhuman pri-
mates have not demonstrated any evidence of anatomical changes (Dwork et 
al., 2004; Sheryl et al., 2015), further research using modern imaging methods 
is warranted (Oltedal et al., 2015). Due to some of the aforementioned issues, 
ECT is sometimes, perhaps improperly, considered a last resort after all other 
treatment options have failed. 
The mechanisms of action behind the therapeutic effects of ECT remains 
a mystery. Many different hypotheses have been proposed, including mono-
aminergic, neuroendocrine, and neuroplasticity-centered perspectives. While 
most of the evidence for molecular mechanisms has been derived from animal 
models using ECS treatments, new evidence from modern human neuroimag-
ing studies has also emerged in recent years.
2.2.1.1   Clinical administration of ECT
A typical course of ECT takes place in the morning after a night of fasting (K. 
Järventausta, personal communication, 23.11.2018). It consists of placing sets 
of electrodes on the scalp of the patient to monitor EEG and lead the electric 
current to the brain, electrodes on the chest for monitoring the electrocardio-
gram, a blood pressure cuff around the arm, and a pulse oximeter in the finger. 
Patients are not typically intubated, but oxygen is administered through a mask. 
A needle is placed into a vein in the arm for the intravenous administration 
of medication. Since many medications may interact with ECT, medications 
are usually discontinued before the initiation of the treatment course (Lisanby, 
2007). The patient is then anesthetized, either using a volatile anesthetic or an 
intravenous one, and given a neuro-muscular blocking agent such as succinyl-
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choline for muscle relaxation. Motor symptoms of a seizure are also monitored. 
This can be achieved by allowing muscle contraction in a limb, for example, for 
by using a tourniquet around the patient’s ankle before the administration of 
a muscle relaxant. Atropine or other drugs may be used to reduce bradycardia 
and bronchial secretions. During an optimal state of anesthesia, a brief pulse 
of electrical current is passed through the brain. The goal is for this current to 
trigger a generalized cerebral tonic-clonic seizure that affects the entire brain. 
The successful delivery of ECT requires the placement of two electrodes on 
the scalp. The location of the electrodes may differ, with many varying configu-
rations possible (Lisanby, 2007). The location of the electrodes and the intensity 
of the current affects both the efficacy of the treatment and the profile of ad-
verse effects (Sackeim et al., 2000). Bitemporal or bilateral (BT), right unilateral 
(RUL), and bifrontal (BF) are the electrode placements used most frequently 
(Lisanby, 2007). The dose of ECT is measured in millicoulombs, and an effec-
tive dose must be sufficient to induce seizure activity. A typical approach is the 
selection of appropriate dosage based on seizure-threshold titration, in which 
progressively higher amounts of charge are delivered in subsequent treatment 
sessions until a dose above the established seizure threshold is selected.
In the beginning, ECT was given using sine wave stimulation, but this 
method has been since found to be inefficient for seizure induction and have 
a pronounced profile of adverse cognitive effects (Prudic, 2008). Today, brief 
pulse waveform is more commonly used, since it produces an equivalent level 
of efficacy and a much better profile of postictal function (Fujita et al., 2006). In 
brief pulse stimulation, peak stimulus intensity is reached rapidly, reducing the 
amount of excess energy transmitted after neuronal depolarization. Typically 
used pulse widths range from 0.5 to 2 milliseconds (Prudic, 2008). Ultra-brief 
pulses of less than 0.5 milliseconds have also been investigated and found to 
produce fewer cognitive deficits, while still producing sufficient treatment effi-
cacy (Loo et al., 2015).
After the treatment, patients may feel confused and disoriented – partly 
due to anesthesia and partly due to the treatment itself. This state of confusion 
is typically not long lasting (Lisanby, 2007). Memory loss can be present during 
the course of ECT treatments, but memory should gradually return to nor-
mal after the treatments have been stopped. Amnesia of events shortly before, 
during, and after treatment can occur. Other typical but passing side effects 
include headaches and nausea. The frequency of ECT administration, electrode 
placement, stimulus waveforms, pulse width, and intensity of electrical charge 
also contribute to the profile of adverse cognitive effects (Prudic, 2008; Weiner 
et al., 1986).
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2.2.1.2  Research on the mechanisms of ECT
Once an electrical pulse is released from the ECT electrodes, it travels through 
intermediary tissue to the brain and forces stimulation into groups of neurons 
by altering their electrical surroundings and concentrations of ions (Singh 
& Kar, 2017).  Groups of neurons then begin to fire simultaneously, which 
produces the propagation of seizure activity. This abnormal electrical activity 
generalizes throughout the brain and affects brain structures from the cortex 
to hypothalamus and the basal ganglia, although certain brain areas might 
be more specifically involved (Enev et al., 2007). Since methods like repeti-
tive high frequency transcranial magnetic stimulation (rTMS) and transcra-
nial direct current stimulation (tDCS) also stimulate the brain and may act as 
antidepressants without producing seizure activity, it has been proposed that 
the stimulation induced by ECT may also be beneficial, albeit less so than the 
generalized seizure following it (Swartz, 2014).
While the therapeutic efficacy of ECT is traditionally attributed to a gener-
alized seizure, a seizure is not sufficient for achieving the therapeutic response. 
Other EEG characteristics have been intensively studied in recent decades us-
ing computational methods (Mayur, 2006). For example, a low dose of RUL 
ECT has been demonstrated to be relatively ineffective despite producing a 
generalized seizure (Sackeim et al., 1987). The duration of seizure activity has 
also been previously considered to be a marker for adequate therapeutic re-
sponse (Maletzky, 1978), but other studies indicate that this is not likely to 
be the case (Gangadhar et al., 1999; Krystal et al., 1993; Nobler et al., 1993; 
Weiner et al., 1986).
On the other hand, changes in EEG after an ECT treatment may predict 
the clinical outcome. The most common EEG finding thought to be associated 
with the clinical outcome is the slowing of EEG activity during the treatment 
course, especially in the frontal cortex in the delta frequency band (~1-4 Hz) 
(Fink & Kahn, 1957; Perera et al., 2004; Sackeim et al., 1996). It is well known 
from studies of epilepsy that seizures are followed by an immediate period of 
EEG slowing or postictal depression (So & Blume, 2010). The slowing of EEG 
during and acutely after the course of convulsive therapies has been well doc-
umented (Chusid & Pacella, 1952; Kriss et al., 1978; Silfverskiold et al., 1987), 
and appear to be similar in both ECT and pharmacological convulsant treat-
ments (Chatrian & Petersen, 1960). It has also been observed that more pro-
nounced postictal slowing after a single ECT session is associated with more 
rapid responses to ECT (Folkerts, 1996) and clinical improvement (Nobler et 
al., 1993; Suppes et al., 1996). Alternatively, different analysis methods such as 
the fractal dimension of EEG signal can be applied. In a study by Gangadhar 
et al. (1999), smaller postictal fractal dimension (smaller values corresponding 
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to a more isoelectric EEG) at a first ECT predicted remission status after six 
ECTs. Furthermore, increased delta activity has been also suggested to under-
lie clinical improvement after pharmacological and psychotherapeutic inter-
ventions (Buysse et al., 1997). Taken together, this evidence indicates that the 
modulation of cortical slow oscillatory activity seems to be intimately connect-
ed to the mechanisms by which ECT provides its therapeutic efficacy.
Among other markers of efficacy, the upregulation of circulating BDNF 
levels after ECT has been proposed as a putative marker of treatment re-
sponse. Three meta-analyses have focused on the changes in peripheral blood 
BDNF levels after ECT treatment with patients suffering from MDD (Brunoni 
et al., 2014; Polyakova et al., 2015; Rocha et al., 2016). The meta-analysis by 
Polyakova et al. (2015) consisted of four studies, with a total of 108 patients, 
looking at plasma BDNF levels, and found an increase following ECT. A pos-
itive correlation between plasma BDNF levels and the number of ECT treat-
ments was also noted. In another meta-analysis by Rocha et al. (2016), results 
from nine studies, with a total of 207 patients, indicated that BDNF levels in 
serum or plasma increased in MDD patients following ECT treatments. Final-
ly, Brunoni et al. (2014) looked at 11 studies, with a total of 221 patients, and 
found that when combining serum and plasma data, BDNF levels increase 
after ECT. However, it is important to note that none of above meta-analy-
ses show a relationship between BDNF changes and antidepressant responses. 
Contrasting results have also been published, with Ryan et al. (2018) reporting 
no difference in plasma BDNF levels 1-3 days after the end of ECT treatment. 
In their study, 61 medicated MDD patients and 50 healthy controls were inves-
tigated. They also reported no differences in levels of plasma BDNF between 
baseline controls and medicated MDD patients or between ECT responders 
and non-responders. 
The regulation and function of blood BDNF is poorly understood. Hu-
man platelets are known to be rich in BDNF (Fujimura et al., 2002; Rosenfeld 
et al., 1995), which is released during blood coagulation and can be easily mea-
sured from serum (Naegelin et al., 2018). A recent study reported that human 
and rat megakaryocytes express BDNF mRNA in a similar manner to neurons, 
though BDNF was undetectable in mouse megakaryocytes – a finding in line 
with the absence of BDNF in mouse serum (Chacón-Fernández et al., 2016). 
These results suggest that megakaryocytes are the main source of blood BDNF. 
However, the mechanisms of how the BDNF levels measured from blood re-
flect brain BDNF remain unclear. Notably, many factors influence peripheral 
BDNF levels, and a high inter-individual variability exists in plasma (Lom-
matzsch et al., 2005) and serum BDNF (Naegelin et al., 2018). The levels of 
plasma BDNF have been shown to vary within a day and between days, with 
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highest levels occurring in the morning and a trend of constant decreasing 
towards the night suggestive of circadian regulation (Begliuomini et al., 2008). 
While the connection of brain BDNF with peripheral BDNF is not yet 
fully elucidated, levels of serum BDNF have been shown to correlate with lev-
els of cortical BDNF in rats (Karege et al., 2002). Electroconvulsive shock has 
also been shown to alter levels of BDNF-related micro-RNAs (miRNAs) both 
in rat brains and blood (Ryan et al., 2013). In addition, ECS regulates the 
expression of many immediate-early genes (IEGs) with specific temporal pat-
terns (Dyrvig et al., 2014). Preclinical evidence has accumulated regarding the 
neurotrophic effects of ECS in rodents, for which ECS – as well as MAOIs 
and SSRIs – increased the expression of BDNF in the hippocampus (Nibuya 
et al., 1995). Similar increases in BDNF levels after ECS in rats have also been 
observed in other studies. For example, Altar et al. (2003) reported that after 
10 daily ECS treatments, BDNF levels were upregulated in the frontal cortex, 
entorhinal cortex, parietal cortex, hippocampus, striatum, and septum. They 
noted that BDNF increased gradually in the frontal cortex and hippocampus, 
with peak responses occurring by the fourth day. Li et al. (2007) also reported 
an increase of hippocampal BDNF after a 14 day ECS treatment course, ac-
companied by increases in locomotor activity and decreased immobility in the 
FST. In addition, O’Donovan et al. (2012) investigated the effects of ultra-brief 
pulse (UBP) (0.3 ms) and brief pulse (BP) (0.5 ms) ECS in naïve rats and 
found increases in cell proliferation within the dentate gyrus with BP-treated 
animals after an ECS course of three treatments a week for 22 days. They also 
reported an increase in hippocampal BDNF and a lower immobility time in an 
FST after an BP ECS, while for UBP these results were not statistically signifi-
cant. Intriguingly, a similar study using the corticosterone model of depression 
in rats reported the effects of BP and UBP ECS in the FST and the increases in 
BDNF protein in the hippocampus to be essentially equipotent (O’Donovan et 
al., 2014). The upregulation of activity-dependent Bdnf transcripts along with 
dendritic spine remodeling have also been reported in a chronic stress model 
of depression in mice after ECS (Maynard et al., 2018). 
The increased expression of BDNF after ECS is thought to regulate diverse 
molecular actions by binding to its cognate receptor TrkB, a receptor tyrosine 
kinase that mediates the phosphorylation of tyrosine residues in accompany-
ing proteins (Reichardt, 2006). Once activated by its ligand, TrkB receptors 
dimerize and become autophosphorylated in their catalytic domains (tyrosine 
residues 701, 705, and 706), which results in increased kinase activity (Cun-
ningham & Greene, 1998; Middlemas et al., 1994; Segal et al., 1996; Stephens 
et al., 1994), however, recent evidence indicates that TrkB monomers may also 
initiate cellular signaling (Zahavi et al., 2018). The activated receptor kinase 
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leads to further activation of the receptor and to the formation of docking 
sites for adaptor proteins. In short, tyrosine 515 recruits adaptor proteins Shc 
and fibroblast growth factor receptor substrate 2 (FRS2) to activate signaling 
through the Ras –  mitogen-activated protein kinase (MAPK, i.e. extracellular 
signal-regulated kinase ERK) pathway and the phosphatidylinositol 3-kinase 
(PI3K) –  Akt (i.e. Protein kinase B) pathway, while tyrosine 816 is the binding 
site for phospholipase Cγ (PLCγ) (Figure 3). Additionally, adaptor proteins 
may also associate with phosphotyrosine residues in the catalytic domain (for 
thorough reviews, see Kaplan & Miller, 2000 and Minichiello, 2009). 
TrkB-induced activation of downstream pathways orchestrates diverse 
effects on synaptic plasticity, proliferation, differentiation, and cell survival 
(Alonso et al., 2004; Gonzalez et al., 2016; Huang & Reichardt, 2003). For 
example, the MAPK pathway leads to the translocation of p44/42-MAPK into 
the nucleus and to the further regulation of transcription factors, such as cyclic 
AMP response element binding protein (CREB) (Patterson et al., 2001; Ying 
et al., 2002). The activation of the PI3K –  Akt pathway leads downstream to 
the activation of the mammalian target of rapamycin (mTOR) and its down-
stream effector p70S6 kinase (p70S6k) (Kumar et al., 2005; Takei et al., 2004), 
further promoting trophic actions and protein synthesis. Akt may also phos-
phorylate glycogen synthase kinase 3 β (GSK3β) in the serine 9 residue, es-
sentially inhibiting the actions of this promiscuous kinase (Eleonore Beurel et 
al., 2015). Moreover, the activation of PLCγ activates the enzyme to hydrolyze 
phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and 
inositol trisphosphate (IP3), which act as second messengers regulating pro-
tein kinase C (PKC) and intracellular Ca2+ release leading to the activation of 
Ca2+/calmodulin (Ca2+/CaM) dependent protein kinases (CaMKK and CaM-
KIV) (Reichardt, 2006). In particular, this tyrosine 816 mediated signaling ap-
pears important for hippocampal synaptic plasticity, since a point mutation of 
the residue impairs signaling through calcium-dependent protein kinases to 
CREB (Minichiello et al., 2002).
Since increased BDNF-TrkB signaling has been proposed to be sufficient 
to explain the effects of traditional antidepressants in rodents (Koponen et 
al., 2005; Saarelainen et al., 2003; Shirayama et al., 2002; Siuciak et al., 1997), 
the activation of TrkB may also hold relevance for ECT. Surprisingly, there 
are not many studies investigating TrkB activation in the preclinical context. 
One study investigated the total and phosphorylated levels of BDNF receptor 
TrkB in the rat hippocampus after a 10-day ECS treatment regimen (Enomoto 
et al., 2017). The study reported an increase in both BDNF levels and TrkBY706 
phosphorylation while the total levels of TrkB were downregulated, suggesting 
ligand-induced downregulation of the receptor. Conversely, in another study, 
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Figure 3. Main signaling pathways of the BDNF receptor TrkB. Phosphorylation 
upon BDNF binding can happen in the catalytic domain (Y701/Y705/Y706), the Shc 
binding site (Y515), or the PLCγ binding site (Y816). The activated receptor may re-
cruit adaptor proteins to signal through the Ras –  MAPK pathway, the PLCγ pathway, 
and the PI3K –  Akt pathway, which lead to diverse cellular changes.
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TrkBY706 phosphorylation in the rat prefrontal cortex (PFC) was not found to 
be regulated acutely by ECS treatment, while p44/42-MAPK signaling was ro-
bustly increased (Hansen et al., 2007). Increased MAPK signaling has also 
been reported by others acutely in the rat hippocampus  (HC) (Kang et al., 
2002), PFC, cerebellum (Jeon et al., 1998), and after repeated ECS treatments, 
in the PFC (Kang et al., 2006). In addition, increased phosphorylation (func-
tional inhibition) of GSK3βS9 has also been reported after acute ECS in the HC 
and PFC of mice (Basar et al., 2013) and rats (Roh et al., 2003).
Increased neurogenesis after ECS has been consistently reported in the lit-
erature. Madsen et al. (2000) demonstrated neurogenesis in the dentate gyrus 
of rats treated with 10 ECS seizures, with many of the newborn cells displaying 
a neuronal phenotype. Moreover, Perera et al. (2007) reported similar effects in 
adult nonhuman primates. Increased hippocampal neurogenesis has also been 
observed with ECS after chronic corticosterone administration (Hellsten et al., 
2002), and has been reported to be necessary for antidepressant-like behavioral 
changes in a corticosterone model of depression (Schloesser et al., 2015). Fur-
thermore, Olesen et al. (2017) demonstrated using chronic restraint stress and a 
clinically relevant ECS schedule in rats that the newly born neurons survive up 
to 12 months, but are not associated with increases in mobility in the FST. In 
addition, increases in hippocampal dendritic arborization (Smitha et al., 2014) 
and the regulation of markers associated with synaptogenesis (Okada-Tsuchio-
ka et al., 2014) have been associated with ECS in rats. These intriguing find-
ings, along with the fact that hippocampal atrophy is present in MDD, may at 
least partly explain neuroimaging studies showing hippocampal enlargement 
in humans after ECT (Dukart et al., 2014; Nordanskog et al., 2010; Tendolkar 
et al., 2013). In a meta-analysis comprising of eight studies with a total of 193 
participants, ECT was found to increase volumes of both the hippocampus 
and the amygdala (Takamiya et al., 2018). These findings have paved the way 
for the hypothesis of hippocampal enlargement as a potential biomarker for 
treatment outcome of ECT in severely depressed patients. However, a recent 
study indicates that hippocampal enlargement in humans does not seem to be 
associated with the clinical outcome of ECT (Oltedal et al., 2018).
Modern functional imaging technologies have also provided the ability 
to study brain connectivity. Indeed, abnormalities in the connectivity of neu-
ronal networks have been hypothesized to underlie the mood symptoms of 
depressed patients (Kaiser et al., 2015; Wang et al., 2012). Three important 
networks known as the affective network, the cognitive control network, and 
the default mode network have been proposed to mediate different aspects of 
the disorder such as decreased focus, rumination, and emotional dysregulation 
(Sheline et al., 2010). In particular, an fMRI study of depressed patients noted 
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increased resting state functional connectivity from these three networks to a 
bilateral dorsal medial prefrontal cortex region and vice versa (Sheline et al., 
2010). They suggest that reducing the increased connectivity to this area could 
be a potential target for the treatment of depression.  Moreover, Perrin et al. 
(2012) investigated the acute effects of ECT on global functional connectivi-
ty and found a decrease localized to a limited area within the left dorsolater-
al prefrontal cortex (DLPFC), an area of the brain previously implicated in 
depression and cognitive function (Steele et al., 2007). On the other hand, 
Liu et al. (2015) reported an increase in the local activity and connectivity 
of the subgenual anterior cingulate cortex (sgACC) and suggested that these 
changes play a key role in the mechanisms underlying the effectiveness of ECT. 
Pretreatment connectivity measures of the DLPFC and sgACC have also been 
proposed to predict ECT treatment outcomes in a recent study (Leaver et al., 
2018). Taken together, these results suggest that the therapeutic mechanisms of 
ECT may include the normalization of hyper- or hypoconnectivity of certain 
brain networks. 
Since prefrontal slowing, diminished cerebral blood flow, reduced me-
tabolism, and altered connectivity are all present during the postictal state of 
ECT, this state has been suggested to underlie the key mechanism of the action 
of ECT (Krystal & Weiner, 1999). The findings of increased BDNF expres-
sion following seizure activity (Duman et al., 1997) suggest that neurotrophic 
signaling mechanisms might mediate the possible reactivation or rewiring of 
diminished connectivity among neuronal networks. Drawing together many 
studies, Farzan et al. (2014) proposed a connectivity resetting hypothesis of 
ECT action, which postulates that the therapeutic effects of ECT are mediated 
through resetting patterns of neural connectivity. They suggest that this reset-
ting takes place through networks such as thalamocortical pathways, which 
further modulate cortical neuronal oscillations. Importantly, evidence of in-
creased intra- and internetwork connectivity in support of network reconfig-
uration is emerging (Wang et al., 2018). Many similar changes have also been 
observed with ketamine, another rapid-acting treatment of depression, as will 
be discussed in the next chapter.
2.2.2 Ketamine
Ketamine was first synthesized in 1962 by the Parke-Davis pharmaceutical 
company, following the discovery of phencyclidine (PCP), another arylcyclo-
hexylamine dissociative anesthetic (Denomme, 2018). Due to PCP’s unwanted 
profile of effects, many of its subsequent derivatives were screened in animal 
experiments by Parke-Davis pharmacologists. From these experiments, ket-
amine emerged as the lead compound. After animal testing, ketamine was first 
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given to prisoners in studies led by EDwARD DOMINO and was found to be a 
safe and short-acting anesthetic in humans. Many of the peculiar psychotropic 
effects of PCP, however, were still present. Thus, ketamine was coined as a dis-
sociative anesthetic (Domino et al., 1965).
Ketamine is the mixture of two optical stereoisomers: S(+) and R(-)-ket-
amine. It is pharmaceutically produced in both racemic and enantiopure 
preparations. Its main pharmacological mechanism of action is the blocking 
of NMDARs, a key component of glutamatergic excitatory neurotransmission 
(MacDonald et al., 1991). The enantiomers of ketamine have slightly different 
effects. S-ketamine is often preferred in clinical anesthesia due to its more po-
tent activity at blocking NMDARs, while R-ketamine has a much lower affinity 
for NMDARs (Zanos et al., 2018). Based on animal experiments, R-ketamine 
has been proposed to be the ideal isomer for treatment of depression due to its 
less pronounced profile of psychotomimetic effects (Yang et al., 2015), however 
no clinical evidence exists for the superiority of either isomer.
The classical NMDAR antagonists ketamine, PCP, and MK-801 are all 
non-competitive inhibitors of NMDAR ion channels (Bolshakov et al., 2003; 
MacDonald et al., 1991). They exhibit a trapping block by entering the ion 
channel and then being captured inside the closing pore. Some other NMDAR 
antagonists, such as memantine, are thought to act as partial trapping blockers 
– only hindering the channel closure but not entirely preventing it (Blanpied 
et al., 1997). Ketamine has also been proposed to have many other targets, in-
cluding dopaminergic, serotonergic, adrenergic, opioidergic, cholinergic, and 
sigma receptors. It also has effects on serotonin, noradrenaline, and dopamine 
uptake transporters (SERT, NET, DAT respectively) and ion channels, such as 
voltage-gated sodium channels (VGSC) (Haeseler et al., 2003) and hyperpolar-
ization-activated cyclic nucleotide gated (HCN) channels (Zhou et al., 2013). 
For a review of ketamine’s pharmacology, see Zanos et al. (2018).
Ketamine is rapidly distributed in the body, has low plasma protein bind-
ing, and a short elimination half-life of two to four hours (Clements & Nimmo, 
1981; Mathew & Zarate, 2016). While (R,S)-norketamine (NK) is the initial me-
tabolite, (2R,6R;2S,6S)-hydroxynorketamine (HNK) and (R,S)-dihydronor-
ketamine (DHNK) are among the major circulating metabolites in human 
plasma after a typical ketamine infusion used in the treatment of depression 
(Zarate et al., 2012; Zhao et al., 2012). Peak plasma concentrations are reached 
in approximately 1.3 hours for NK and 3.8 hours for DHNK and HNK (Zhao 
et al., 2012). Plasma levels of HNK and DHNK are still significantly elevated 
24 hours after the infusion and can be detected for up to 48 hours in some 
patients. The initial N-demethylation to NK is mainly catalyzed by liver cyto-
chrome P450 enzymes CYP2B6 and CYP3A4, followed by hydroxylation into 
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hydroxynorketamines and dehydronorketamine (Portmann et al., 2010). Sev-
eral minor metabolic pathways also exist (Adams et al., 1981; Woolf & Adams, 
1987). Ketamine’s metabolism and pharmacokinetics are reviewed thoroughly 
by Zanos et al. (2018).
The dissociative anesthesia produced by ketamine is different from many 
other sedatives and anesthetics as it is not a sedative or a hypnotic drug (Sinner 
& Graf, 2011). Ketamine-induced blockade of NMDARs leads to the occurrence 
of dissociative states, where patients may experience being conscious while be-
ing drawn away from their sensory perception (Mathew & Zarate, 2016). The 
level of dissociation is dose-dependently increased, with higher doses deepen-
ing into hallucinatory-like states of open and closed-eye visuals and extreme 
perturbations of thought and bodily sensation (Garfield et al., 1972). Patients 
going through ketamine anesthesia often report dream-like states unlike any-
thing experienced previously, such as sensations of traveling through space 
and time while being detached from bodily sensation. Anesthetic doses induce 
a state of total dissociation often accompanied by amnesia, since NMDARs are 
crucial components of long-term potentiation and memory formation. Some 
of these psychoactive properties of ketamine have been sought by recreational 
users, as evidenced by the surge in recreational use in the 1970s that continues 
to this date (Mathew & Zarate, 2016).
Due to its unique mechanism of action, ketamine is also considered to 
be safe for emergency anesthesia in a prehospital setting. The dosing range 
is relatively wide, and ketamine supports cardiovascular function due to its 
sympathomimetic action, maintains respiratory function, and provides effec-
tive analgesia comparable to morphine (Marland et al., 2013). Following its 
Food and Drug Administration (FDA) approval in the 1970s, these proper-
ties prompted the use of ketamine on American soldiers during the Vietnam 
War. Today, ketamine is often employed in emergency units for anesthesia and 
widely used for procedural sedation in a variety of patient populations, from 
children to adults (Sinner & Graf, 2011). Ketamine is not preferred for general 
anesthesia performed at hospitals due to its potent psychotropic effects and 
the potential to produce emergence phenomena, manifesting as profound con-
fusion or hyperexcitation upon waking up from the dissociative state in up to 
20% of adults (Marland et al., 2013). However, these side-effects of ketamine 
were desirable in the psychiatric investigations in the 1970s, which consisted of 
using ketamine as an “abreactive agent.” A variety of doses more than capable 
of producing psychotropic experiences were employed in early trials (Khor-
ramzadeh & Lotfy, 1973). While intriguing anecdotes of facilitated psychother-
apeutic responses in psychiatric patients were described, it took close to three 
decades before the first scientifically rigorous investigations were launched. 
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Berman et al. (2000) were the first to demonstrate the rapid-acting antidepres-
sant effects of ketamine in patients suffering from MDD. These results have 
since been replicated in several clinical trials (Lapidus et al., 2014; Murrough 
et al., 2013; Zarate, Singh, Carlson, et al., 2006). Ketamine’s effects take place 
within hours of drug administration and these effects may last for days or weeks 
after a single dose. In addition, the antidepressant-like effects of ketamine have 
been demonstrated in various animal models (Autry et al., 2011; Li et al., 2011; 
Maeng et al., 2008). However, the psychoactive properties and abuse liability 
of ketamine have hindered its widespread clinical application in treating de-
pression (Krystal et al., 1994). Perhaps partly due to the stigma associated with 
hallucinogenic drugs, research on ketamine has been mostly focused on utiliz-
ing the lowest possible doses with minimal psychoactive effects. A large interest 
also exists in developing treatments that mimic the action of ketamine without 
its psychotropic side effects. While preclinical and clinical investigations have 
figured out many of the effects that ketamine has in the brain, the precise neu-
robiological basis of its rapid antidepressant effects remains a mystery.
2.2.2.1  Clinical administration of ketamine
Doses of ketamine in the induction of anesthesia are typically in the range of 1 
to 2 mg/kg intravenously, which produce dissociative anesthesia within one to 
two minutes of injection (Marland et al., 2013).  When ketamine is used for the 
treatment of depression, intravenous doses from 0.1 to 0.5 mg/kg are commonly 
employed (Andrade, 2017). The first randomized controlled trials demonstrat-
ing ketamine’s efficacy used an IV dose of 0.5 mg/kg over 40 minutes (Berman et 
al., 2000; Zarate, Singh, Carlson, et al., 2006). This dosage and route of admin-
istration have been adopted by many clinicians since. According to C. Zarate, 
ketamine is typically administered in research settings during the morning for 
convenience (personal communication, 23.11.2018). The peak of antidepressant 
effects occurs 24 hours after an infusion, but most patients experience a relief of 
their depressive symptoms within two to four hours of administration. Dissoci-
ation is variably present during the infusion, but most patients can still answer 
questions. Once the 40-minute infusion ceases, the patients are for the most part 
neither in sedation or stimulation states, but are more talkative and active, as in 
a non-depressed state (C. Zarate, personal communication 23.11.2018).
Ketamine can be administered orally, sublingually, intranasally, intramus-
cularly, and subcutaneously, but best bioavailability is achieved by intravenous 
or intranasal administration (Andrade, 2017). Notably, a recent open longitu-
dinal study suggested that a rapid ketamine bolus of 0.5 mg/kg also has rapid 
antidepressant effects (Vidal et al., 2018).  Recent clinical trials also indicate the 
antidepressant action of intranasal (Daly et al., 2018; Lapidus et al., 2014) and 
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per oral (Arabzadeh et al., 2018; Domany et al., 2018) ketamine administration. 
In clinical practice, ketamine treatments can be repeated and dosages can be 
increased if patients do not respond to initial administration (Andrade, 2017). 
Consecutive sessions may be also used to extend and maintain antidepressant 
effects.
A typical course of experimental ketamine treatment in the Turku Univer-
sity Hospital in Finland consists of a psychiatric evaluation, electrocardiogram 
(ECG) and blood pressure measurements, and urine and plasma screenings 
before the initiation of treatment (Taiminen, 2017). Racemic ketamine is then 
continuously infused at a dose of 0.5 mg/kg over 40 minutes. Blood pressure 
is constantly monitored during the ketamine infusion and the patient is kept 
in the hospital for at least four hours after the treatment. If the treatment re-
sponse is evident, the patient may receive additional treatments twice a week 
for a period of one to two weeks. Treatment can be then continued for up to 
three months with ketamine infusions once a week. During the course of the 
treatment, ECG, blood pressure, and screenings are checked monthly. 
Despite the widespread use of ketamine in clinical practice, the safety of 
long-term ketamine administration remains a continuing concern. Ketamine 
impairs memory function acutely, and may cause prolonged memory problems 
when used in high doses for longer periods of time (Morgan & Curran, 2006). 
While the findings of jOhN OlNEy in the 1980s were suggestive of NMDAR 
antagonist-induced neurotoxicity (Olney et al., 1989) – so-called Olney’s le-
sions in rodents – neurotoxicity in primates likely requires significantly higher 
doses. However, neuroimaging studies of chronic ketamine users have indicated 
cortical atrophy and reductions in prefrontal gray matter after two to four years 
of ketamine abuse (Liao et al., 2011; Wang et al., 2013). Notably, the majority 
of the subjects in the Wang et al. study were using 1 g of ketamine a day – far 
beyond the dosage range used in the treatment of depression or even in anes-
thesia. Cognitive deficits have also been observed in users who used ketamine 
more than four times a week (Morgan et al., 2010). Since there are no reports of 
ketamine anesthesia-induced neurocognitive deficits despite its widespread use, 
it is likely that ketamine produces significant neurotoxicity only after chronic 
administration of very high doses. The safety and tolerability of long-term ket-
amine treatments for depression thus must be carefully studied.
2.2.2.2  Research on the mechanisms of ketamine
Since the breakthrough clinical trial of Berman et al. (2000) reporting the rap-
id-antidepressant effects of a single continuous infusion of 0.5 mg/kg ketamine 
over 40 minutes in treatment-resistant patients, most studies have followed 
along similar dosages of ketamine (Diazgranados et al. 2010, Valentine et al. 
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2012, Murrough et al. 2013). These sub-anesthetic dosages at slow rates of in-
fusion are described to produce only minor psychoactive effects, avoiding the 
more psychedelic states produced by higher but still sub-anesthetic dosages. 
Similar treatment outcomes have also been observed with a single intranasal 
administration of 50 mg of ketamine (Lapidus et al. 2014). The potential of 
intranasal ketamine has also been investigated by Janssen in their clinical trial 
comparing the effects of 28, 56, and 84 mg doses of S-ketamine (Daly et al. 
2018). Interestingly, this study found that the higher doses produced a lon-
ger-lasting remission of depressive symptoms. In addition to its antidepressant 
effects, intranasal administration of S-ketamine (84 mg) has also been reported 
to reduce suicidality in patients at imminent risk for suicide (Canuso et al., 
2018). Most importantly, in a recent double-blind active placebo-controlled 
trial of various subanesthetic ketamine doses, only the higher doses of 0.5 mg/
kg and 1.0 mg/kg were found to have clinically meaningful effects (Fava et al., 
2018).
While impressive numbers of individual trials have investigated the effi-
cacy of ketamine in treating MDD, the literature still lacks solid evidence for 
dose-dependent effects or the minimum effective dosage for achieving anti-
depressant responses. The practice of using low doses of ketamine in treating 
depression seems sensible if the psychedelic or dissociative effects intervene 
with the antidepressant outcome, but evidence for this is lacking. On the con-
trary, some studies suggest that the opposite could be true. For example, Loo 
et al. (2016) investigated the effects of ketamine dose titration in depressive 
patients with intravenous, intramuscular, and subcutaneous routes of delivery. 
The placebo-controlled pilot trial consisted of 15 patients, with ascending dos-
es rather than randomized design. They found no differences between meth-
ods of administration, but the dose required for the antidepressant response 
differed between individuals, suggesting that dose titration should be done on 
an individual basis. A higher dose resulted in greater antidepressant response 
as well as greater psychotomimetic effects. These results are also in line with 
a meta-analysis by Xu et al. (2016), who performed a systematic review and 
meta-analysis of nine trials with ketamine. Six trials were categorized as a low 
dose (0.5 mg/kg IV) and three trials tested a very low dose of ketamine (one 50 
mg intranasal spray, one 0.1-0.4 mg/kg IV and one 0.1-0.5 mg/kg IV or SC). 
They reported that a low dose of ketamine appears to be more effective than 
a very low dose, but that there is substantial heterogeneity in the clinical re-
sponse, with one-fifth of patients showing remission of symptoms at one week, 
but most others showing benefits that were not as enduring. Additionally, Lai 
et al. (2014) compared different doses (0.1, 0.2, 0.3, 0.4 mg/kg) of ketamine 
administered to four patients as an IV infusion over five minutes in a dou-
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ble-blind, placebo-controlled, crossover design. They presented dose-response 
data of both ketamine efficacy and psychoactive effects and proposed that an-
tidepressant efficacy may be dose related, and that psychoactive effects were 
dose-related. 
Some trials have reported evidence that points towards the importance 
of dissociative or psychoactive effects in producing concurrent antidepres-
sant responses. For example, a double-blind, cross-over, placebo-controlled 
clinical trial by Sos et al. (2013) found a substantial relationship between 
the antidepressant response and the psychotomimetic effects elicited by ket-
amine treatment. Their trial shows that more intense psychotomimetic symp-
toms (as assessed by the Brief Psychiatric Rating Scale (BPRS)) correlated 
with improved mood ratings on the Montgomery-Åsberg Depression Rating 
Scale (MADRS) seven days post-ketamine infusion. Luckenbaugh et al. (2014) 
investigated whether the psychoactive effects of ketamine are important to 
the subsequent antidepressant effects. They analyzed 108 treatment-resistant 
depressive patients from three studies, of which two were double-blind and 
the third had an open-label design. In these studies patients received a single 
subanesthetic dose (0.5 mg/kg) of ketamine via an intravenous infusion over 
40 minutes. Ratings of depression, hypomania, mania, psychotomimetic, and 
dissociative symptoms were measured using the Hamilton Depression Rating 
Scale (HDRS), the Young Mania Rating Scale (YMRS), the BPRS, and the 
Clinician Administered Dissociative States Scale (CADSS). Psychiatric ratings 
were collected before and at 40, 80, 110, and 230 minutes after the start of in-
fusion, and at various time points post-infusion. The correlation of increased 
CADSS at 40 minutes and improvement in HDRS at 230 minutes and on day 
seven were found to be significant. However, changes in YMRS, BPRS total, 
or BPRS positive symptoms at 40 minutes were not found to be correlated 
with the improvement of HDRS. Luckenbaugh et al. concluded that the pres-
ent correlation suggests that dissociative side effects may serve as a clinical 
biomarker to predict ketamine’s efficacy. Most recently, a study reported that 
dissociative symptoms measured by the CADSS were found to be related to 
the antidepressant responses after 0.5 mg/kg of ketamine (Niciu et al., 2018). 
However, contrasting results have also been published that show no correla-
tion between maximum CADSS and HDRS responses at any time following 
ketamine infusion (Valentine et al., 2011). 
Some researchers have proposed that the antidepressant effects cannot be 
separated from the dissociation and/or psychedelia, and that these are central 
to successful treatment when combined with psychotherapy (Wolfson 2014). 
An intriguing recent clinical trial, however, demonstrated that the antidepres-
sant effects of ketamine can be attenuated with the administration of an opioid 
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receptor antagonist naltrexone, while the dissociative effects are still present 
(Williams et al., 2018). However, the small number of patients in this trial limit 
the possibility of making thorough conclusions. 
Preclinical studies of ketamine have focused on identifying important neu-
ronal, molecular, and metabolic targets of ketamine. The first preclinical work 
suggesting antidepressant-like action of NMDAR antagonists in the FST was 
done by Trullas and Skolnick (1990) in mice. They demonstrated that the com-
petitive NMDA antagonist AP-7 and non-competitive antagonist MK-801 both 
reduced the immobility of animals subjected to the FST, similar to the tricyclic 
antidepressant imipramine. Following these findings, Skolnick et al. (1996) 
demonstrated that chronic antidepressant treatments change radioligand bind-
ing to NMDARs in the cerebral cortex and proposed NMDARs as a common 
pathway for traditional antidepressant action. Additional evidence for the rap-
id-antidepressant behavioral effects of ketamine, MK-801, and Ro25-6981, a 
selective antagonist for the NMDAR subtype 2B (NR2B), have since been pub-
lished (Maeng et al., 2008). Ketamine, however, was found to produce the most 
sustained responses.
Since NMDARs are crucial mediators of excitatory glutamatergic neuro-
transmission, one could expect their inhibition to lead to decreased neuronal 
excitability. Intriguingly, among one of the most prevailing hypotheses of ket-
amine’s antidepressant action is the disinhibition hypothesis, which proposes 
that ketamine’s antidepressant action is due to the preferential inhibition of 
NMDARs present in gamma-aminobutyric acid (GABA) producing interneu-
rons, leading to decreased inhibition of excitatory pyramidal neurons and in-
creased glutamatergic signaling at subanesthetic doses in rodents (Figure 4) 
(Homayoun & Moghaddam, 2007; Moghaddam et al., 1997). Another proposed 
cellular hypothesis of ketamine’s action revolves around the direct antagonism 
of extrasynaptic NMDARs present on pyramidal neurons, which disrupt the 
tonic activation of NMDARs by ambient glutamate and trigger homeostatic 
synaptic plasticity alterations and compensatory increases of excitatory drive 
in the prefrontal cortex (Miller et al., 2016). In particular, these changes are 
thought to be mediated by the blockade of extra-synaptic NMDARs contain-
ing NR2B subunits (Miller et al., 2014). Ketamine has also been proposed 
to inhibit spontaneous NMDAR-mediated miniature excitatory post-synaptic 
currents (mEPSCs) and to trigger increases in the translation of proteins such 
as BDNF by reducing the phosphorylation of eukaryotic elongation factor-2 
(eEF2), leading to antidepressant-like effects (Autry et al., 2011; Nosyreva et 
al., 2013; Sutton et al., 2007). In addition, decreased activation and burst firing 
of neurons in the lateral habenula after ketamine administration has been as-
sociated with acute antidepressant effects in congenitally helpless rats, which 
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otherwise display abnormal NMDAR-dependent firing and helpless behavior 
(Yang et al., 2018).  These hypotheses, however, do not exclude each other, 
and might all be contributing to the molecular alterations seen after ketamine 
administration.  
The excitatory effects of ketamine seem to be very dose dependent, with 
anesthetic doses of 200 mg/kg intraperitoneally (IP) administered decreasing 
acute glutamate activity measured by microdialysis in rats and lower doses of 
10, 20, and 30 mg/kg increasing glutamate outflow in the prefrontal cortex 
(Moghaddam et al., 1997). Ketamine has been also shown to provoke transient 
changes in glutamate cycling in the medial prefrontal cortex (mPFC) of rats 
(Chowdhury et al., 2017). This surge in glutamate after ketamine administra-
tion has been proposed to underlie the rapid-acting antidepressant effects, per-
haps via the regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic 
acid receptors (AMPARs), since AMPAR blockade with NBQX abolishes an-
tidepressant-like behavioral responses in mice and rats (Koike & Chaki, 2014; 
Koike et al., 2011; Maeng et al., 2008). Moreover, positive allosteric modulators 
of AMPARs produce antidepressant-like behavioral effects in rodents (Knapp 
et al., 2002; Li et al., 2001) and increase the synthesis of BDNF (Lauterborn et 
al., 2000; Mackowiak et al., 2002). 
Rapid synaptic neurotransmission in the brain is mediated by AMPARs, 
which are ionotropic transmembrane glutamatergic receptors (Derkach et al., 
2007). These receptors play a key role in the regulation of activity-dependent 
changes in the synaptic strength of excitatory synapses and are involved in nu-
merous complex signaling pathways that regulate synaptic plasticity. AMPARs 
are constantly in dynamic motion to and from the postsynaptic membrane. 
NMDAR activation and the following Ca2+ influx is thought to play a role in 
the lateral diffusion and incorporation of GluR1 subunit containing AMPAR 
from extrasynaptic sites to the synapses thus promoting synaptic potentiation. 
Small GTPases Ras and Rap have been found to control AMPAR trafficking 
and synaptic potentiation through mechanisms requiring p44/42-MAPK ac-
tivation (Zhu et al., 2002). Moreover, p44/42-MAPK is downstream of Ras/
MEK (MAPK/ERK kinase), which is downstream of Ca2+/calmodulin-de-
pendent protein kinase kinase (CaMKK). CaMKK is sensitive to Ca2+ eleva-
tion, providing a putative route of signaling for early long-term potentiation 
(e-LTP) expression (Derkach et al., 2007; Schmitt et al., 2004). The late phase 
of LTP (L-LTP) also requires changes in the transcription of genes and the 
synthesis of new proteins (Derkach et al., 2007). Among these proteins are pro-
posedly AMPAR subunits and other components involved in regulating their 
movement. Additionally, many proteins important for the structural changes 
in dendritic spines are thought to be produced, perhaps via the translocation 
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Figure 4. Overview of proposed molecular mechanisms underlying ketamine’s rapid an-
tidepressant action. (A) Disinhibition hypothesis: ketamine blocks NMDARs on GABAergic 
inhibitory interneurons, which leads to decreased inhibitory tone on excitatory pyramidal neu-
rons. Increased glutamate release acts on postsynaptic AMPARs and induces cellular effects, 
e.g. BDNF release, TrkB activation, and the regulation of downstream pathways important for 
plasticity and protein synthesis, including the activation of MAPK and mTOR and the regu-
lation of AMPAR dynamics and scaffolding proteins like PSD95. (B) Hydroxynorketamine 
metabolites modulate postsynaptic AMPAR signaling leading to downstream changes. (C) 
The inhibition of GSK3β by ketamine reduces phosphorylation of PSD95T19, which augments 
AMPAR signaling by reducing the internalization of AMPAR subunits. (D) Ketamine blocks 
extrasynaptic NMDARs that are normally tonically activated by glutamate and disinhibits 
mTOR activity. (E) The blockade of spontaneous NMDAR-mediated neurotransmission leads 
to the disinhibition of BDNF translation via eEF2-dependent mechanisms.
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of polyribosomes from dendritic shafts into spines for local translation (Os-
troff et al., 2002).
Among other important molecular targets, the inhibition of GSK3β by 
ketamine via the phosphorylation of Ser9 residue has been suggested to be 
necessary for the rapid antidepressant-like effects observed in mice (Beurel et 
al., 2011). This inhibition can take place through Akt (Zhou et al., 2014) and re-
duces the phosphorylation of postsynaptic density protein 95 (PSD-95) Thr19 
residue, which augments AMPAR-mediated signaling by diminishing the inter-
nalization of GluA1 subunits (Beurel et al., 2016). Inhibition of GSK3 has also 
been shown to potentiate the synaptogenic and antidepressant-like effects of a 
subthreshold dose of ketamine in rats (Liu et al., 2013). However, contradicto-
ry results by Ma et al. (2013) failed to demonstrate long lasting-antidepressant 
effects of a GSK3β inhibitor in a model of chronic stress in mice. Importantly, 
GSK3β is a promiscuous kinase with multiple targets and the precise mecha-
nisms of its regulation are difficult to ascertain (Li & Jope, 2010).
Molecular investigations into the intracellular effects of ketamine in rats 
have revealed the rapid regulation of the mammalian target of rapamycin 
(mTOR) pathway as an important molecular alteration. The mTOR is partic-
ularly important for cellular protein synthesis, along with increased synaptic 
protein levels and the formation of spines in the prefrontal cortex after small 
doses of ketamine (5-10 mg/kg, IP) (Li et al., 2010). In this study, phosphory-
lation changes were observed within 30 minutes in mTOR, 4E-BP1, ERK1/2, 
Akt, and p70S6K proteins in isolated synaptoneurosomes, while synaptic pro-
teins Arc, Synapsin I, PSD95, and GluR1 were upregulated after two hours. 
In addition, the blockade of mTOR activity using rapamycin (ICV) abolished 
the effects of ketamine on synaptogenesis and in behavioral assays, suggest-
ing these changes are dependent on mTOR-driven protein synthesis. Li et al. 
(2010) also reported that, unlike a dose of 10 mg/kg, 80 mg/kg of ketamine 
failed to reduce immobility time in the FST. These results further support the 
idea of a specific dosage range of ketamine in promoting acute glutamatergic 
excitability and the subsequent intracellular effects required for antidepres-
sant-like effects. Based on the current evidence, it is likely that ketamine not 
only exerts differential dose-dependent effects on neuronal activity, but also 
temporally varying effects.
Some studies have pinpointed the actions of ketamine on the infralimbic 
prefrontal cortex (IL-PFC) in rodents. For example, the inactivation of IL-
PFC using muscimol has been demonstrated to block the antidepressant-like 
behavioral actions of ketamine, while a microinfusion of ketamine to the IL-
PFC essentially recapitulated the effects of systemic ketamine administration 
(Fuchikami et al., 2015). Moreover, optogenetic stimulation of the IL-PFC 
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produced rapid and sustained antidepressant effects that were associated with 
increases in the number and function of spines. The authors highlight the im-
portance of neuronal activity in producing ketamine’s effects. Moreover, the 
latest research has also implicated a subtype of pyramidal neurons in the an-
tidepressant effects of ketamine. The study assessed Drd1 and Drd2 dopamine 
receptor-expressing pyramidal neurons and found that the optogenetic acti-
vation of Drd1 pyramidal cells of the mPFC produced rapid and long-lasting 
antidepressant effects, while Drd2 neuron stimulation was ineffective (Hare et 
al., 2019).
To make things more complicated, it may be that the regulation of molec-
ular events important for antidepressant-like effects cannot deduced from the 
effects of ketamine alone. Notably, recent study by Zanos et al. (2016) demon-
strated that the ketamine metabolite HNK was sufficient to promote rapid an-
tidepressant-like responses in mice, and that the metabolism of ketamine to 
HNK was required for these responses. They suggested these effects of HNK 
may be independent of NMDAR inhibition, involving a more direct activa-
tion of AMPARs instead. Moreover, (2R,6R)-HNK was proposed to act as the 
more potent enantiomer in exerting antidepressant-like effects on a behavior-
al and molecular level. The authors further support this hypothesis with the 
previous findings that R-ketamine is more potent than S-ketamine in mouse 
models of depression, and that the antidepressant effects of S-ketamine are 
not sustained over 24 hours. Moreover, in this study, MK-801 did not exert 
sustained antidepressant-like effects in mice, which could be argued to be due 
to the lack of active metabolites. Furthermore, they demonstrated that a deu-
terated ketamine analogue, that is minimally metabolized into HNK, did not 
produce ketamine-like behavioral effects. Consistent with the idea of AMPAR 
activation driving the antidepressant-like effects, the blockade of AMPAR with 
NBQX prevented both the acute and sustained antidepressant-like behavior-
al effects of (R,S)-ketamine and (2R,6R)-HNK and ameliorated the acute in-
crease of EEG gamma oscillations (Zanos et al., 2016). Since HNK did not 
seem to produce the unwanted psychotropic effects of ketamine, this study 
immediately gained enormous attention.
Controversy around this hypothesis was also imminent, as evidenced by 
the correspondence of Collingridge et al. (2017). In their letter to the editor, 
they dispute the idea of NMDAR-independent antidepressant effects of ket-
amine and bring up various translational problems in interpreting findings 
from animal models to humans. According to their letter, S-ketamine has been 
estimated to be around two times as potent as racemic ketamine in humans, cit-
ing a clinical trial by Singh et al. (2016). Although this study does not directly 
compare the ketamine isomers, Singh et al. demonstrated around two weeks 
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of sustained antidepressant effects after S-ketamine administration, contrary to 
the effects seen in mice by Zanos et al. (2016). Since S-ketamine is unlikely to 
be metabolized into (2R,6R)-HNK, Collingridge et al. (2017) conclude that 
these observations are consistent with NMDAR antagonism as the principal 
mechanism of action. Moreover, Collingridge et al. underline that comparing 
ketamine with MK-801 is difficult, since they possess different properties in 
blocking the NMDARs, and that the therapeutic effects of NMDAR antag-
onists seem to be associated with their affinity and voltage dependence. This 
is also evidenced by memantine, which binds with a low affinity and has not 
been demonstrated to function as an antidepressant in humans. Following the 
findings of Zanos et al. (2016) on the NMDAR-independent antidepressant 
actions of HNK, Suzuki et al. (2017) published a study where they assessed 
NMDAR-mediated mEPSCs in cultures of hippocampal neurons. Most im-
portantly, they demonstrated that (2R,6R)-HNK does indeed inhibit synap-
tic NMDARs and triggers the phosphorylation of eEF2 similarly to ketamine. 
However, they also suggest that these ketamine metabolites may explain the 
sustained antidepressant effects of ketamine, which some other NMDAR an-
tagonists are lacking. Many questions, however, remain unanswered regarding 
the molecular alterations ketamine induces in animal models and how these 
changes are connected to its antidepressant effects in humans.  
Human brain imaging studies have demonstrated normalized global func-
tional connectivity after subanesthetic ketamine treatment (Abdallah, Averill, 
Collins, et al., 2017; Abdallah, Averill, Salas, et al., 2017) and changes in the 
balance of frontoparietal connectivity patterns (Muthukumaraswamy et al., 
2015). A recent double-blind, placebo-controlled crossover study used fMRI 
to demonstrate that connectivity between the insula and the default mode net-
work (DMN) was normalized in MDD patients when compared to healthy 
controls two days post-ketamine infusion (Evans et al., 2018). Furthermore, 
this change was reversed after 10 days, in line with the duration of ketamine’s 
antidepressant effects. Evans et al. (2018) used a triple network model of con-
nectivity dysfunction between the DMN, salience (SAL), and central execu-
tive (CEN) networks as their working model, which has been suggested to be 
the cornerstone of psychiatric and neurological disorders, including depres-
sion (Menon, 2011). This hypothesis proposes that in MDD, the activity of the 
DMN is increased (Hamilton et al., 2015), while activity in the SAL and CEN 
networks are reduced (Menon, 2011). The DMN is a network implicated in 
introspective thought and ruminative thought patterns, while SAL mediates 
salient information processing from the outside world and CEN is important 
in working memory function and attentional processes. Since the insula is in-
volved in the integration of external emotional stimuli and processing of exter-
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nal information, the authors suggest increased connectivity between the insula 
and DMN after ketamine may suggest an improved ability to process external 
stimuli and thus the improvement of symptoms (Evans et al., 2018).
The effects of ketamine may also vary depending on the baseline conditions 
of the subjects, since ketamine has been reported to have distinct electrophys-
iological – as measured by magnetoencephalography – and behavioral effects 
when given to depressed or healthy subjects (Nugent et al., 2017). While MDD 
patients show rapid improvements in depressive symptoms, healthy controls 
may display increases in depressive symptoms for up to a day after ketamine 
administration. Additionally, Nugent et al. (2017) reported that MDD patients 
who had lower baseline gamma power but displayed high gamma power after 
ketamine administration responded better to the treatment. These increases 
in gamma power lasted for up to nine hours post-ketamine infusion in both 
healthy controls and MDD patients, suggesting changes in synaptic plastici-
ty that greatly outlast the infusion period. Furthermore, the authors propose 
gamma power as a potential marker of synaptic homeostasis. In support of the 
idea that baseline conditions affect the outcomes of ketamine treatments, mice 
have been found to elicit glutamate functional hyperconnectivity in the chron-
ic social defeat model of depression (McGirr et al., 2017). Administration of su-
banesthetic ketamine to these mice resulted in large global cortical glutamate 
transients. Similar effects were observed in naïve mice that were subjected to 
local cortical inhibition of glutamate transporters and subsequently given ket-
amine, suggesting a unique sensitivity to subanesthetic ketamine after chronic 
social defeat stress.
Clinical evidence indicates that the metabolic activity of the prefrontal 
cortex is increased in healthy volunteers after subanesthetic ketamine adminis-
tration (Breier et al., 1997). Similarly, increased glutamate neurotransmission 
in the prefrontal cortex of healthy and depressed patients has been reported 
after the patients received ketamine (Abdallah et al., 2018; Li et al., 2016). In-
triguingly, in rats, ketamine doses up to 60 mg/kg produce behavioral arousal 
and increase theta range EEG activity but show no activation of the sleep-pro-
moting nuclei of the ventrolateral preoptic nucleus (VLPO) of hypothalamus, 
as measured with Fos immunoreactivity (Lu et al., 2008). Instead, ketamine 
was found to activate subcortical wakefulness-promoting nuclei. In the same 
study, animals that were administered a high dose of 150 mg/kg of ketamine 
showed signs of hyperarousal upon awakening. Furthermore, two hours after 
ketamine administration, the expression of Fos in the cerebral cortex, arousal 
systems, and VLPO were reported to be similar as with the lower dosages that 
were arousal-promoting. This arousal-promoting effect of NMDA antagonists 
is followed by a subsequent period of rebound sleep with markedly increased 
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delta frequency power in rats (Campbell & Feinberg, 1996; Feinberg & Camp-
bell, 1995). Intriguingly, increased slow-wave activity (SWA) has been report-
ed in humans during sleep following subanesthetic ketamine administration, 
and this has been proposed to predict the therapeutic efficacy of the treatment 
(Duncan, Sarasso, et al., 2013). In addition to increases in slow EEG oscilla-
tions, baseline delta-sleep ratios have also been implicated in rapid antidepres-
sant responses after ketamine (Duncan, Selter, et al., 2013).
The mechanistic link between increased neuronal excitability and the in-
duction of increased slow EEG activity remains unclear. However, the phe-
nomena of increased SWA after prolonged sleep deprivation (Huber et al., 
2000) or somatosensory stimulation (Kattler et al., 1994) has been reported 
in mice and also in humans after rTMS (Huber et al., 2007) or ECT (Sackeim 
et al., 1996). Combining the variety of known effects of ketamine on synaptic 
plasticity processes, functional connectivity changes, neuronal metabolism, 
and the regulation of sleep and wakefulness are instrumental in understanding 
ketamine’s multifaceted profile of effects.
2.2.3 Other putative treatments
Emerging evidence supports the idea that multiple drugs besides ketamine 
may possess rapid-acting antidepressant potential. The close association be-
tween ECT-induced post-seizure neuronal inhibition and its therapeutic effica-
cy (Fink & Kahn, 1957) encouraged researchers a few decades ago to test the 
antidepressant actions of isoflurane anesthesia in depressive patients (Langer 
et al., 1985). Isoflurane is a potent volatile halogenated ether general anesthet-
ic. Its mechanism of action is not entirely known, but it appears to modulate 
both NMDARs and GABARs among other targets (Jones et al., 1992; Krasows-
ki & Harrison, 2000; Ming et al., 2001). Isoflurane anesthesia deep enough to 
provoke burst suppression EEG patterns has been demonstrated to produce 
antidepressant effects comparable to those of ECT in double-blind (Langer et 
al., 1995, 1985; Weeks et al., 2013) and open-label study designs (Engelhardt et 
al., 1993). These effects seem to take place relatively rapidly after the first treat-
ment. Isoflurane has also been demonstrated to produce antidepressant-like 
behavioral effects in animal models of depression and to activate signaling 
pathways relevant to the antidepressant-like effects of ketamine in mice (Antila 
et al., 2017; Brown et al., 2018). In particular, isoflurane has been shown to 
activate TrkB and mTOR signaling while inhibiting GSK3β activity (Antila 
et al., 2017). Moreover, isoflurane was demonstrated to facilitate LTP in the 
hippocampus, to increase the activity of parvalbumin interneurons, and to fa-
cilitate GABAergic neurotransmission. These changes appeared 24 hours after 
anesthesia.
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Propofol is another general anesthetic that engages NMDARs and GABARs 
and has been reported to produce rapid-antidepressant effects comparable to 
ECT in a small open label trial (Mickey et al., 2018). The antidepressant effects 
of anesthetic doses of propofol used in this study (9-20 mg/kg) appeared to 
be both rapid and sustained. Like ketamine, propofol is also widely used in 
lower doses for procedural sedation, and has a rapid onset and offset of action 
combined with an acceptable safety profile (Lamperti, 2015). Notably, propo-
fol produces dose-dependent decreases in cortical activity similar to isoflurane 
(Pilge et al., 2014). Further studies are required to validate the putative antide-
pressant effects of propofol, including possible dose-dependent effects, and to 
elucidate the molecular changes that take place in the brain during and after 
propofol anesthesia.
The effects of another anesthetic, nitrous oxide (N2O), were investigated in 
a psychiatric context already decades ago. In a study conducted by Brill et al. 
(1959), schizophrenic and depressive patients received either ECT, ECT and 
succinylcholine, ECT and thiopental, thiopental alone, or N2O alone. The au-
thors noted that all treatments contributed to symptomatologic improvement, 
however, the low sample sizes did not allow for statistical significance. More re-
cently, a mixture of 50% N2O and 50% O2 was given to patients suffering from 
treatment-resistant depression in a small blinded placebo-controlled crossover 
trial (Nagele et al., 2015). The subjects inhaled the gas for 1 hour and depres-
sive symptoms were measured at 2 hours and 24 hours post-inhalation. Ni-
trous oxide produced a marked and rapid alleviation of depressive symptoms 
in some patients when compared to a placebo. Nitrous oxide is also regularly 
used in procedural sedation and as an additive to more potent anesthetics. Its 
minimum alveolar anesthetic concentration (MAC) is estimated to be 1.04 atm 
in humans (Hornbein et al., 1982) and even greater in rats (Gonsowski & Eger 
2nd, 1994). Due to this, N2O is rarely used as a sole anesthetic, but instead 
often combined with other, more potent general anesthetics such as isoflurane 
or sevoflurane.
Nitrous oxide is known to act as an NMDAR antagonist (among other tar-
gets) similar to ketamine (Mennerick et al., 1998; Yamakura & Harris, 2000), 
but the intracellular neuronal mechanisms triggered by nitrous oxide treatment 
remain relatively unstudied. Notably, the molecular effects of N2O have not 
been investigated in the context of depression. Nitrous oxide administration 
at subanesthetic concentrations produces dissociative and psychotropic effects 
relatively similar to other dissociative anesthetics (Block et al., 1990; Ghoneim, 
2001). Moreover, N2O has been shown to induce cell proliferation in the dentate 
gyrus of rat hippocampi, similar to ketamine, which is suggestive of neurogen-
esis (Chamaa et al., 2018). Notably, N2O is known to paradoxically regulate 
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slow EEG oscillations in humans by blunting slow EEG activity during admin-
istration (unlike other anesthetics) and causing prominent rebound increases in 
slow EEG activity after the cessation of the gas flow (Foster & Liley, 2011, 2013; 
Henrie et al., 1961; Williams et al., 1984). Some studies also report increases in 
higher frequency EEG oscillations during gas inhalation (Rampil et al., 1998). 
One proposed mechanism for the cortical activation during N2O treatment 
may be the increased release of noradrenaline in the cerebral cortex (Yoshida 
et al., 2010). However, the relationship of these neurobiological effects to their 
putative antidepressant potential is unknown.
The antimuscarinic agent scopolamine has been shown to produce anti-
depressant effects in small randomized placebo-controlled clinical trials (Dre-
vets & Furey, 2010; Furey & Drevets, 2006). In these trials, scopolamine hydro-
bromide was administered as an intravenous infusion of 4 μg/kg. Significant 
clinical responses were observed three to four days after the first treatment, 
suggestive of a slightly slower onset of antidepressant effects compared to ket-
amine. These responses have been reported to last for more than two weeks 
after the final treatment. However, in a recent randomized, placebo-controlled, 
crossover trial, Park et al. (2018) reported no significant antidepressant effects 
of scopolamine in treating MDD. Results from animal experiments suggest 
that increases in glutamatergic transmission, activation of mTOR signaling 
pathways, and synaptogenesis are associated with scopolamine as well as ket-
amine (Voleti et al., 2013). Moreover, ketamine and scopolamine have both 
been shown to provoke transient changes in glutamate cycling in the mPFCs 
of rats (Chowdhury et al., 2017). 
Drugs like psilocybin, LSD, and dimethyltryptamine that act on serotoner-
gic receptors, especially the 5HT2A-receptor, have been investigated as potential 
psychiatric treatments in the past (Dos Santos et al., 2016). While many of these 
studies are indicative of beneficial effects, most of the studies are limited by size 
and protocol. In a more recent small open-label feasibility study of psilocybin 
for treatment-resistant depression, a rapid improvement of depressive symp-
toms was reported (Carhart-Harris et al., 2016). In this trial, the symptoms of 
depression were reduced for up to three months or more in some patients. Due 
to major limitations of the study, such as the low number of participants and tri-
al design, no thorough conclusions can be made about the therapeutic efficacy 
of psilocybin in treating MDD. However, psilocybin has also been investigated 
in a double-blind placebo-controlled crossover trial in treating patients strug-
gling with severe cancer and related psychological stress (Ross et al., 2016). 
This study reported rapid and robust anxiolytic and antidepressant effects that 
endured for at least seven weeks. Upcoming clinical trials will likely unravel the 
potential that psychedelics may hold as rapid-acting antidepressants.
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The most researched non-pharmacological treatment of depression is sleep 
deprivation. This old experimental practice holds the potential to provide rap-
id and notable amelioration of depressive symptoms (Boland et al., 2015). In 
sleep deprivation, patients are kept awake for prolonged periods of time, which 
results in reduced depressive symptoms for some patients. The effects of sleep 
deprivation are often short-lived and modest in size, with symptoms returning 
within days. There is no clear knowledge of the mechanism of how sleep depri-
vation elicits its effects (Wu & Bunney, 1990). After sleep deprivation, patients 
exhibit increased rebound slow wave sleep in subsequent sleep periods (Berger 
& Oswald, 1962; Nakazawa et al., 1978). Moreover, sleep deprivation causes 
prominent changes in the expression of c-Fos in the rat brain, indicative of 
cortical activation among other areas (Cirelli et al., 1995). Findings from func-
tional imaging suggest increases in the connectivity of the dorsal nexus to the 
prefrontal cortex occur in humans after sleep deprivation (Bosch et al., 2013). 
Moreover, high pretreatment rates of metabolism and subsequent decreases in 
metabolic rates of the medial prefrontal cortex have been proposed to char-
acterize patients whose depressive symptoms improve after sleep deprivation 
(Wu et al., 1999; Wu et al., 2008).
Since the discovery of the rapid-acting antidepressant effects of ketamine, 
clinical research has been carried out with a variety of different drugs, but to 
date, none of them have produced effects comparable to those of ketamine – 
that is, rapid and robust antidepressant efficacy in treatment-resistant MDD 
that is sustained from days to weeks (Henter et al., 2018). Among the drugs that 
have been investigated for their rapid-antidepressant effects is memantine, an 
uncompetitive NMDAR antagonist at the PCP-binding site like ketamine. No-
tably, memantine has failed to produce antidepressant effects in double-blind 
placebo controlled clinical trials (Lenze et al., 2012; Zarate, Singh, Quiroz, et 
al., 2006). Relatively rapid antidepressant effects were observed in one study, 
but this was an open-label trial utilizing dose titration (Ferguson & Shingle-
ton, 2007). These results may be explained by the pharmacodynamic proper-
ties of memantine, which is a low-affinity voltage-dependent antagonist with 
a half-life of 60-100 hours in humans (Matsunaga et al., 2018). It has a unique 
binding affinity, receptor kinetics, strong voltage dependency, and preference 
for receptor subtypes and thus brain areas (Parsons et al., 1995; Porter & Gre-
enamyre, 1995). Unlike ketamine, memantine only exhibits partial trapping of 
the NMDAR ion channels (Blanpied et al., 1997) and has differential effects on 
receptor desensitization (Glasgow et al., 2017). All the aforementioned prop-
erties essentially make memantine a very different type of NMDAR antagonist 
compared to ketamine. Notably, one of the proposed mechanisms of action 
for the use of memantine in the treatment of neurodegenerative diseases is its 
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neuroprotective properties against glutamatergic excitotoxicity (Parsons et al., 
1999), while the antidepressant effects of subanesthetic ketamine have been 
linked to acutely increased glutamate bursting (Moghaddam et al., 1997). Rec-
reational users have reported that memantine can produce potent dissociative 
effects (Erowid, 2018), but only at doses much higher than those investigated 
in clinical trials.
Investigational drugs in development include but are not limited to, 
NMDAR glycine site antagonists, NR2B antagonists, NMDAR glycine site 
partial agonists, mGluR2/3 antagonists, and mGluR5 negative allosteric mod-
ulators (Henter et al., 2018). NMDAR antagonists such as MK-0657 (aka 
CERC-301) (Ibrahim et al., 2012) and AZD6765 (aka lanicemine) (Sanaco-
ra et al., 2017), mGluR2/3 antagonist RO4995819 (ClinicalTrials.gov, 2018b), 
mGluR5 antagonist AZD2066 (ClinicalTrials.gov, 2018a), and mGluR5 nega-
tive allosteric modulator RO4917523 (basimglurant) (Quiroz et al., 2016) have 
produced disappointing results in clinical trials, despite having displayed po-
tential effectiveness in animal studies. The difficulty in translating preclinical 
findings into clinically effective rapid-acting antidepressants thus remains a 
major issue and may require further understanding of the molecular mecha-
nisms of rapid-acting treatments and the formulation of animal models that 
are more representative of the key mechanisms mediating rapid antidepressant 
responses.
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3 AIMS OF THE STUDY
There is huge unmet medical need for safer, more efficient, and reliable rap-
id-acting antidepressants. In addition to ketamine, several other anesthetics 
like isoflurane (deep anesthesia) and nitrous oxide (subanesthetic) have been 
shown to provide rapid therapeutic effects in depressed patients. Moreover, the 
amelioration of depression has occasionally been observed following a single 
ECT, a phenomenon thought to be linked with postictal EEG slowing. The 
purpose of this thesis is to utilize such diverse treatments carrying rapid anti-
depressant potential to find shared neurobiological principles underlying an 
immediate remedy against major depression. 
The specific aims of the study are as follows:
I investigating phosphoproteomic alterations induced by burst-suppressing 
isoflurane anesthesia, 
II investigating the effects of diverse rapid-acting antidepressants on EEG 
and molecular signatures implicated in ketamine’s antidepressant effects 
and
III investigating the dose-dependent effects of ketamine on TrkB and GSK3β 
signaling.
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4 MATERIALS AND METHODS
The main methods and contributions by the author of this thesis are listed in 
Table 1. More detailed information on these procedures can be found in the 
original publications.
Table 1. Methods and author (S.K.) contributions 
Method Used in Author personally involved
Experimental design I, II, III II, III
Pharmacological treatments I, II, III I, II, III
Brain dissection I, II, III I, II, III
Tissue processing I, II, III I, II, III
qPCR II II
EEG surgery I, II, III II
EEG recordings I, II, III II
EEG analysis I, II, III
Behavioral experiments II
Phosphoprotein enrichment I I
LC-MS analysis I
Bioinformatics I
Writing of manuscript I, II, III I, II, III
Statistics I, II, III I, II, III
Figures I, II, III I, II, III
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5 RESULTS
5.1 Phosphoproteomic investigation of the effects  
  of brief isoflurane anesthesia (I)
Previous clinical studies have indicated that isoflurane anesthesia is capable 
of producing rapid antidepressant effects comparable to those of ECT, with-
out the pronounced cognitive side-effects (Langer et al., 1985, 1995). However, 
the mechanisms of action of isoflurane anesthesia remain unknown. Moreover, 
very little is known about the subcellular events following general anesthesia. 
In general, pharmacological agents can be expected to have a myriad of effects 
on protein phosphorylation pathways, yet only a few selected targets can be 
investigated using antibody-based detection of western blots. Thus, we utilized 
liquid chromatography tandem mass spectrometry (LC-MS/MS) based anal-
ysis coupled with titanium dioxide phosphopeptide enrichment to investigate 
the molecular alterations set forth by a brief isoflurane anesthesia without a 
priori assumptions. To our knowledge, this is the first phosphoproteomic study 
concerning the effects of anesthesia in samples obtained from the mammalian 
brain.
We first validated the stable expression of an EEG burst suppression pat-
tern in mice using 4% isoflurane anesthesia for induction and 2% isoflurane 
for maintenance during a 30 min period. This protocol of isoflurane anesthesia 
is also commonly used in animal experiments requiring surgical anesthesia. 
Similar treatment protocol was then used to anesthetize the mice from which 
the brain samples were collected. We found altogether 318 significant phos-
phorylation alterations in a total of 237 proteins between the isoflurane anes-
thetized and sham treated mice. A number of phosphorylation hits represented 
the primary pharmacological targets of anesthetics, such as the phosphoryla-
tion of GABAA α1-subunit Ser373 and Thr366, GABAB β3-subunit Ser394, and 
NMDAR NR2B subunit Ser1036 and Tyr1039 residues. In addition, several 
other proteins implicated in a variety of biological processes were identified, 
including members of solute carriers, ion channels, kinases, and phosphatases. 
Among these changes, robust regulation of GSK3β at the inhibitory Ser9 resi-
due was identified – a molecular change previously implicated in the rapid-an-
tidepressant actions of ketamine. Moreover, reduced phosphorylation of the 
activating loop residues of p44/42-MAPKT202/Y204 and increased phosphoryla-
tion of microtubule-associated protein 2 (MAP2) residues Thr1620,1623 were 
found. Intriguingly, both of these proteins have been also implicated in mech-
anisms of antidepressants and plasticity (Bianchi & Baulieu, 2012; Li & Jope, 
2010).
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The results of the phosphoproteomic analysis were validated using western 
blotting and commercially available antibodies for GSK3βS9, p44/42-MAPKT202/
Y204, and MAP2T1620/1623. In further experiments, we demonstrated that these 
three protein targets were all similarly regulated by sevoflurane, urethane, and 
ketamine – suggesting that these intracellular events are common to all the an-
esthetics investigated regardless of their somewhat different pharmacological 
targets (Figure 5). 
Figure 5. Diverse anesthetics produce similar acute phosphorylation changes on 
p44/42-MAPKT202/Y204, GSK3βS9, and MAP2T1620/1623 in the adult mouse hippocampus. 
(A) Effects of isoflurane anesthesia (4% induction, 2% maintenance; 30 min) (N = 10/
group). (B) Effects of sevoflurane anesthesia (6% induction, 4.5% maintenance; 30 min) 
(N = 6/group). (C) Effects of urethane anesthesia (2.0 g/kg, IP; 30 min) (N = 4/control 
group, N = 6/urethane group). (D) Effects of subanesthetic ketamine (100 mg/kg, IP.; 
30 min) (N = 6/group). *p < 0.05, **p < 0.01, ****p < 0.0001; two-tailed unpaired t test 
with Welch’s correction.
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Our results provide a foundation for the use of quantitative phosphoproteom-
ics in investigating the neurobiological mechanisms of anesthetic drugs and 
raise important questions about the functional significance of these phos-
phorylation changes. Most importantly, these results suggest that isoflurane, 
sevoflurane, urethane, and ketamine all regulate the phosphorylation changes 
of GSK3βS9, p44/42-MAPKT202/Y204, and MAP2T1620/1623 in a similar manner. Fur-
thermore, our results demonstrate that a brief isoflurane anesthesia regulates a 
myriad of molecular changes that may be confounding factors in many experi-
mental models investigating alterations in cellular signaling.
5.2 Shared neurobiological mechanisms of  
  ketamine, nitrous oxide, and flurothyl (II)
Among the shared properties of the clinically effective rapid-acting treatments 
ECT and ketamine is the capacity of these treatments to regulate cortical ex-
citability and to modulate several molecular pathways implicated in neuronal 
plasticity. With the intriguing clinical report of nitrous oxide produced rap-
id-acting antidepressant effects by Nagele et al. (2015) in mind, we sought to 
investigate the acute effects of nitrous oxide on EEG parameters and molecular 
alterations in mice. 
We first adopted the treatment protocol used by Nagele et al. (2015) and 
investigated markers of neuronal excitability using quantitative PCR and west-
ern blotting. Mice received 50% N2O mixed with 50% oxygen for an hour, and 
the samples were collected one hour after the cessation of the treatment. Sam-
ples from the medial prefrontal cortex demonstrated the increased expression 
of several immediate-early genes: c-fos, Arc, Bdnf, Zif-268, Homer1A, Egr-2, Mkp-1 
and Synapsin I (Figure 6a). Similar changes were also observed in experi-
ments with continued N2O administration for a duration of two hours after 
which samples were collected (Figure 6b). Phosphorylation of p44/42-MAP-
KT202/Y204 was also found to be increased after a 30 min N2O treatment along 
with the upregulated expression of c-fos mRNA (Figure 6C). These results 
suggest increased excitatory tone in the prefrontal cortex under the effects of 
N2O. Importantly, these changes bear resemblance to those reported after ECS 
(Dyrvig et al., 2014) and sleep deprivation (Cirelli et al., 1995). 
The administration of subanesthetic ketamine produced an acute in-
crease in gamma EEG oscillations, a marker of neuronal activity, followed by 
increased slow EEG oscillations after ketamine’s elimination (Figure 7a). 
These properties prompted us to investigate the EEG alterations arising af-
ter the cessation of N2O treatment. No clear EEG alterations were observed 
during exposure to 50% N2O, but upon gas withdrawal, slow EEG oscillations 
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increased above baseline values (Figure 7b). We further tested a higher dose 
of 75% N2O in a shorter 20-minute exposure to investigate this rebound emer-
gence of slow oscillations and found a rapid increase in delta-frequency power 
after the cessation of 75% N2O, which could be repeated by intermittent dosing 
(Figure 7C). 
Figure 6. (A) Levels of Arc, Bdnf, c-fos, Egr-2, Homer-1a, Mkp-1, Synapsin 1, and Zif-268 
mRNA after continuous administration of N2O (50%) for 1-h and a 1h washout peri-
od. (B) Arc, Bdnf, and c-fos mRNA levels are similarly upregulated by 2-h continuous 
N2O (50%) and 1-h N2O (50%) followed by a 1-h washout period. (C) c-fos mRNA and 
p-MAPKT202/ Y204 levels are increased after 30 min of N2O (50%) administration. Data are 
means ± S.E.M. *< 0.05, **< 0.01, ***< 0.001
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Figure 7. (A) Representative time frequency EEG spectrogram and normalized pow-
er of EEG oscillations after a subanesthetic dose of ketamine (KET; 10 mg/kg, IP) Su-
banesthetic ketamine evokes rebound delta oscillations gradually after the acute effects 
of the drug on high gamma oscillations have dissipated. (B) Slow wave delta (1–4 Hz) 
and theta (4–7 Hz) EEG oscillations are transiently increased upon N2O (50%) with-
drawal. (C) Rebound delta oscillations after discontinuation of 75% N2O treatment. 
Data are means ± S.E.M.
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The activation of TrkB, inhibition of GSK3β, and regulation of mTOR signal-
ing have been implicated in antidepressant-like behavioral effects in rodents 
(Beurel et al., 2011; Li et al., 2010; Saarelainen et al., 2003). We investigated 
how these molecular pathways are regulated during acute nitrous oxide ex-
posure and during the subsequent withdrawal period. Samples from animals 
exposed to N2O for a 30 min period did not show any regulation of the afore-
mentioned pathways (Figure 8a). However, samples collected during the 
withdrawal period, 5 or 15 minutes after exposure to N2O, demonstrated statis-
tically significant phosphorylation changes (Figure 8b-C). In particular, 65% 
N2O was found to produce increased phosphorylation of TrkBY816, GSK3βS9, 
and p70S6KT421/S424 (a downstream effector of mTOR) after both 5 and 15 min-
utes during a period of increased slow EEG oscillations (Figure 8b-C).
The emergence of post-ictal slow EEG activity is also observed in patients 
following seizures induced with ECT or flurothyl, and this phenomenon has 
been proposed to predict both the efficacy and onset of the antidepressant ef-
fects of convulsive therapies (Fink & Kahn, 1957; Folkerts, 1996; Nobler et al., 
1993; Perera et al., 2004; Sackeim et al., 1996; Suppes et al., 1996). We admin-
istered flurothyl to mice in amounts that produced a generalized seizure that 
was terminated rapidly upon drug withdrawal. During the post-ictal period, 
a robust increase in delta power emerged while the animals appeared motion-
less and sedated, as evidenced by reduced electromyogram activity (Figure 
9a). When samples were collected during this post-ictal period, the robust reg-
ulation of TrkBY816, GSK3βS9, and p70S6KT421/S424 was evident (Figure 9b). 
These data suggest that putative rapid-acting antidepressants evoke TrkBY816, 
GSK3βS9, and p70S6KT421/S424 alterations as during homeostatically generated 
slow EEG oscillations in response to the preceding period of cortical exci-
tation.
To test whether the direct facilitation of slow EEG oscillations without 
preceding excitation can also produce these effects, we used medetomidine, a 
hypnotic-sedative drug commonly used in veterinary anesthesia. Medetomi-
dine increased slow EEG oscillations, but did not produce any acute chang-
es in the expression of IEGs (Figure 10a,C). Most intriguingly, a sedative 
dose of medetomidine robustly activated TrkBY816, GSK3βS9, and p70S6KT421/
S424 (Figure 10b), suggesting direct facilitation of slow EEG oscillations to be 
sufficient for the activation of these pathways. 
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Figure 8. (A) Levels of p-TrkBY816, p-GSK3βS9, and p-p70S6kT421/424 after 30 min of N2O 
(50%) administration. (B) Levels of p-TrkBY816, p-GSK3βS9, and pp70S6kT421/424 at 5-min 
post-N2O exposure (50–75%). (C) Levels of p-TrkBY816, p-GSK3βS9, and p-p70S6kT421/424 
at 15-min post-N2O exposure (65%). Data are means ± S.E.M. *< 0.05, **< 0.01, ***< 
0.001.
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Figure 9. (A) Representative time frequency EEG spectrogram and normalized 
power of major EEG oscillations after flurothyl induced seizures. Flurothyl evokes re-
bound emergence of slow-wave delta and theta oscillations. (B) Levels of p-TrkBY816, 
p-GSK3βS9, and pp70S6kT421/424 10 min after flurothyl (FLUR) administration. Data are 
means ± S.E.M. *< 0.05, ***< 0.001
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Figure 10. (A) Representative time frequency EEG spectrograms and normalized 
power of major EEG oscillations during 30-min saline and medetomidine (MED; 0.3 
mg/kg, IP) treatment. (B) A low dose of medetomidine (0.05 mg/kg, IP) rapidly in-
creases phosphorylation of TrkBY816, GSK3βS9, and p70S6kT421/424 in the mouse medial 
prefrontal cortex. (C) Levels of Bdnf, c-fos, Arc, Homer1a and Zif268 mRNA 2 h after 
medetomidine (0.3 mg/kg, IP) administration. Data are means ± S.E.M. *< 0.05, **< 
0.01, ***< 0.001
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We found that medetomidine, unlike subanesthetic doses of ketamine, re-
duced the phosphorylation of p44/42-MAPK (Figure 11a). Since increased 
phosphorylation of TrkB-mTOR, GSK3β, and MAPK have been thought to 
be important for ketamine’s antidepressant-like behavioral effects, we tested 
whether medetomidine would produce antidepressant-like behavioral respons-
es without increasing MAPK phosphorylation or regulating immediate-early 
gene expression. We tested both medetomidine (0.05 mg/kg, IP) and ketamine 
(15 mg/kg, IP) in the learned helplessness paradigm and found a single dose 
of subanesthetic ketamine to ameliorate the avoidance deficit, while medetomi-
dine produced no such effect (Figure 11b)
Figure 11. (A) Dose-dependent acute effects (30 min) of ketamine (KET) and effects 
of a low dose of medetomidine (MED; 0.05 mg/kg, IP) on phospho-MAPKT202/Y204. (B) 
Number of escape failures before and 24-h after low-dose ketamine (15 mg/kg, IP) or 
medetomidine (0.05 mg/kg, IP) in the learned helplessness paradigm. Data are means 
± S.E.M. *< 0.05, ***< 0.001
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5.3 The regulation of TrkB-GSK3B signaling by  
  ketamine is dose-dependent (III)
Ketamine is most commonly given in subanesthetic doses (~0,5 mg/kg, IV over 
40 min) for the treatment of depression. However, a number of studies have 
suggested that there is a positive relationship between the antidepressant re-
sponse and the dissociative symptoms produced by the higher-end of subanes-
thetic doses (Lai et al., 2014; Loo et al., 2016; Luckenbaugh et al., 2014; Niciu 
et al., 2018; Sos et al., 2013; Xu et al., 2016). Moreover, a recent animal study 
has suggested that a particular metabolite of ketamine, 6-hydroxynorketamine 
(HNK), is responsible for ketamine’s rapid antidepressant effects (Zanos et al., 
2016). Thus, we sought to investigate how different doses of ketamine modu-
late TrkB-GSK3β signaling and whether these effects rely on ketamine or its 
metabolites. 
Essentially, we investigated the acute effects of ketamine, 6,6-d2-ketamine 
(a deuterated ketamine analogue resistant to metabolism), and cis-HNK on 
TrkB and GSK3β signaling and concomitant electroencephalographic (EEG) 
alterations in the prefrontal cortex of adult mice. A low dose of ketamine (10 
mg/kg, IP) increased gamma high power (60-100 Hz), while a higher dose 
of ketamine (100 mg/kg, IP) prominently facilitated the increase of delta-fre-
quency (1-4 Hz) power along with increases in theta (4-7 Hz), beta (12-25 Hz), 
gamma low (25-40 Hz) and gamma high (60-100 Hz) power, while decreasing 
alpha frequency power (7-12 Hz) (Figure 12a-b). Furthermore, prominent in-
creases in TrkBY816, p70S6kT421/S424, and GSK3βS9 phosphorylation were evident 
30 minutes after a higher dose of ketamine, while a low dose failed to produce 
any changes (Figure 12C). Most importantly, the ability of ketamine to pro-
duce these effects was dose-dependent, with the most significant changes seen 
after an anesthetic dose.
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Figure 12. (A) Normalized power of major EEG oscillations during ketamine (10 
and 100 mg/kg) (data analyzed in 5 min bins). Dashed vertical line indicates injection 
point (0 min). (B) Major EEG oscillation frequency band power of ketamine treatments 
represented as area under curve (AUC) from 30 minutes of recording. (C) Phosphoryla-
tion of TrkBY816, GSK3βS9, and p70S6kT421/424 in the adult mouse medial prefrontal cortex 
30 min after an IP injection of saline (SAL) and ketamine (K10, 10 mg/kg; K100, 100 
mg/kg). Approximate molecular weight (MW) for each protein band of interest is given 
in kilodaltons (kDa). Data are means ± S.E.M. *<0.05, **<0.01, ***<0.005
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To elucidate whether these effects are driven by ketamine or by its metabolite 
HNK, we investigated EEG changes after the acute administration of a high 
dose of cis-HNK (20 mg/kg, IP). cis-Hydroxynorketamine produced negligi-
ble changes on EEG power spectra when compared to saline-treated animals 
(Figure 13b-C). Moreover, tissue samples collected 30 minutes after a similar 
HNK injection failed to demonstrate any changes in TrkBY816, p70S6kT421/S424, 
and GSK3βS9 phosphorylation (Figure 13a).
Figure 13. (A) Phosphorylation of TrkBY816, GSK3βS9 and p70S6kT421/424 in the adult 
mouse medial prefrontal cortex 30 min after an IP injection of saline (SAL) and cis-6-hy-
droxynorketamine (HNK, 20 mg/kg). (B) Normalized power of major EEG oscilla-
tions during HNK (20 mg/kg) (data analyzed in 5 min bins). Dashed vertical line in-
dicates injection point (0 min). (C) Major EEG oscillation frequency band power of 
HNK treatment represented as area under curve (AUC) from 30 minutes of recording. 
Data are means ± S.E.M. *<0.05, **<0.01, ***<0.005
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The possible role of HNK in mediating signaling effects in conjunction with 
the parent drug was further tested by rapid sample collection after a very high 
dose of ketamine and by utilizing a deuterated ketamine analogue resistant to 
metabolism. A very high dose of ketamine (200 mg/kg, IP) produced rapid 
phosphorylation changes in PFC samples collected 3 minutes after the injec-
tion (Figure 14a), when the mice appeared to be sedated. 
Furthermore, mice were administered equal high doses of either 6,6-d2-ket-
amine or ketamine (100 mg/kg, IP). We found that 6,6-d2-ketamine produced 
essentially similar effects on TrkB and GSK3β phosphorylation as an equal 
dose of ketamine (Figure 14b). These findings reveal that the effects of ket-
amine on TrkB-GSK3β signaling are by no means restricted to subanesthetic 
doses and that cis-HNK is not solely responsible for these effects.
 
Figure 14. (A) Ketamine produces increases in TrkBY816, GSK3βS9, and p70S6kT421/424 
in the adult mouse medial prefrontal cortex 3 minutes after an IP injection of saline 
(SAL) or ketamine (KET, 200 mg/kg). (B) Effects of KET (100 mg/kg, IP; 30 min) and 
6,6-dideuteroketamine (d-KET, 100 mg/kg, IP; 30 min) on p-TrkBY816, p-GSK3βS9, and 
p-p70S6kT421/424. Data are means ± S.E.M. *<0.05, **<0.01, ***<0.005
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6 DISCUSSION
6.1 Anesthesia induced phosphoproteomic changes
IT hAS BEEN over 80 years since electroconvulsive therapy was first used to treat psychiatric patients (Cerletti & Bini, 2018). Later, ECT was also found 
to be effective for treating severe depression (Kalinowsky, 1986). One of the 
clinically important markers of ECT’s action is the post-ictal and/or inter-ic-
tal increase in slow EEG oscillations (Fink & Kahn, 1957; Perera et al., 2004; 
Sackeim et al., 1996). This EEG slowing has been suggested to underlie the 
efficacy and onset of action of ECT (Folkerts, 1996; Nobler et al., 1993; Suppes 
et al., 1996), while not much is known about the molecular correlates of this 
particular brain state. Intriguingly, in the 1980s, researchers had already set out 
to investigate whether increasing slow EEG activity and/or burst-suppression 
with volatile anesthetics such as isoflurane could mimic the effects of ECT and 
produce therapeutic effects of their own. Indeed, preliminary results from pilot 
trials with isoflurane have demonstrated effects similar to ECT, without major 
cognitive side effects (Engelhardt et al., 1993; Langer et al., 1995, 1985; Weeks 
et al., 2013). The neurobiological mechanisms activated by isoflurane have, 
however, remained somewhat uncharted.
We investigated the molecular alterations produced by a brief burst-sup-
pressing isoflurane anesthesia in the mouse hippocampi using TiO2-phospho-
peptide enrichment coupled with phosphoproteomics (I). This method can 
recognize global phosphorylation alterations from sample tissue without a pri-
ori knowledge. However, this methodology as such does not allow the analysis 
of changes in precise subdivisions of anatomical structures, such as hippocam-
pal subfields, which may hold differential relevance for depression. Moreover, 
it does not provide any information on whether the changes are taking place in 
neuronal or non-neuronal cells, but rather pools all phosphorylation changes 
together from the sample. It also does not provide an absolute picture of the 
phosphorylation changes, since TiO2-based enrichment is thought to enrich 
phospho-serine/threonine residues better than phospho-tyrosine. With these 
limitations in mind, the vast number of changes demonstrated by our study 
is a solid indicator of the widespread molecular alterations set forth by brief 
burst-suppressing isoflurane anesthesia. Since similar anesthesia procedures 
are very commonly used in preclinical research, these findings raise important 
questions about the confounding effects of anesthesia on phosphoprotein anal-
yses (e.g. immunohistochemistry following transcardiac perfusion) and assays 
in general. This is especially important since some of phosphorylation changes 
elicited by isoflurane appear rapidly after brief exposure and may have long 
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lasting effects on animal behavior (Antila et al., 2017; Brown et al., 2018). 
Altogether, 318 phosphorylation alterations were identified in a total of 
237 proteins, which are fully represented and discussed thoroughly in the orig-
inal publication (I). Here I will focus on selected hits, which are also rele-
vant for the other studies. These hits are GSK3βS9, p44/42-MAPKT202/Y204, and 
MAP2T1620/1623, which were confirmed using western blotting and site-specific 
antibodies. Moreover, we investigated whether the same residues were affected 
by other anesthetics drugs at high doses: ketamine, urethane, and sevoflurane. 
To our surprise, all the anesthetics had similar effects on the phosphorylation 
of these selected molecular targets, even though their pharmacological mecha-
nisms are not entirely identical. For example, the volatile anesthetics isoflurane 
and sevoflurane profoundly increase the activity of inhibitory GABAA receptors 
that are already at clinically relevant concentrations, while drugs like ketamine 
are not known to have similar effects (Krasowski & Harrison, 1999). Further-
more, isoflurane and sevoflurane are known to increase glycine-induced Cl- 
currents, while ketamine does not modulate the glycine receptor. On the other 
hand, ketamine has more potent effects on the inhibition of NMDA receptors 
(Yamakura & Harris, 2000). Urethane likely has the widest profile of pharma-
cological targets. It induced increases in glycine and GABAA receptor function, 
while its inhibition of NMDA and AMPA receptors is considered more modest 
(Hara & Harris, 2002). Based on these findings, we hypothesized that these an-
esthetics may cause some molecular alterations by having similar effects on the 
global brain state (i.e. anesthesia or sedation) despite the differences in their 
main pharmacological targets.
Several of the discovered hits are involved in the regulation of the cyto-
skeleton and microtubule dynamics. Among these, microtubule-associated 
proteins (MAPs) like MAP2 play a role in coordinating the bundling activity 
of microtubules that form anchoring scaffolds for other proteins to interact 
with. MAPs are known to be heavily regulated by phosphorylation, which 
changes their ability to bind to microtubules and stabilize their structure (Sán-
chez et al., 2000). MAP2 phosphorylation in Thr1620/1623 residues is known 
to render its dissociation from microtubules in vitro (Sánchez, Pérez et al., 
2000). Thus, there can be various downstream effects of the phosphorylation 
of MAPs, including changes in the regulation of organelle transport and an-
chorage of protein kinases and phosphatases. The actions of microtubules and 
MAPs have been also been proposed to be relevant for psychiatric disorders 
(Marchisella et al., 2016). Intriguingly, some studies have implicated actions 
on MAP2 in the putative antidepressant effects of neurosteroid drugs (Bianchi 
& Baulieu, 2012; Daftary et al., 2017). The association of microtubule-related 
functions with psychiatric disorders thus remains a promising avenue for fur-
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ther research, which may also hold relevance for the antidepressant effects of 
anesthetic drugs. 
Among the phosphorylation alterations induced by the anesthetics, we ob-
served an increase in the phosphorylation of GSK3β Ser9 residue (I), which 
inactivates (Frame et al., 2001) this promiscuous kinase (Linding et al., 2007). 
This phosphorylation event has been previously suggested to be necessary for 
the rapid antidepressant-like effects of ketamine observed in mice (E Beurel et 
al., 2011). Moreover, we observed a reduction in the p44/42-MAPK phosphor-
ylation of the Thr202/Tyr204 residues with all anesthetics. The MAPK pathway 
has also been implicated in the behavioral effects produced by antidepressants 
and ketamine (Duman et al., 2007; Li et al., 2010; Réus et al., 2014). In particu-
lar, in vivo studies indicate increased phosphorylation of p44/42-MAPK in anti-
depressant effects, while the blockade of MAPK activity using MEK inhibitors 
diminishes these effects (Duman et al., 2007; Pochwat et al., 2017). 
The phosphorylation of p44/42-MAPK is generally thought to increase in 
response to excitatory neuronal activity, and it is increased rapidly and robust-
ly after ECS (Baraban et al., 1993; Bhat et al., 1998; Yamagata et al., 2002). In-
deed, MAPK phosphorylation is increased in ex vivo brain slices by glutamate 
administration and mediates the phosphorylation of the transcription factor 
CREB and the expression of cFos (Vanhoutte et al., 1999). Many studies, in 
the context of rapid-acting antidepressant effects, have investigated the effects 
of subanesthetic doses of ketamine (~10 mg/kg, IP), while the decreased phos-
phorylation of MAPK in our study may represent the molecular changes par-
ticularly associated with more anesthetic states, since we used a dose of 100 
mg/kg. Importantly, Li et al. (2010) reported increased phosphorylation of 
p44/42-MAPK after 10 mg/kg, but not after 80 mg/kg of ketamine when mea-
sured in the PFC of rats one hour after administration. However, they analyzed 
synaptosomal fractions instead of raw lysates. Nevertheless, the differential 
regulation of glutamate dynamics with small and large doses of ketamine re-
mains a plausible explanation for the decrease in MAPK phosphorylation after 
a 100 mg/kg dose of ketamine IP. While 100 mg/kg of ketamine is not sufficient 
to produce surgical anesthesia, it does produce visible behavioral immobility 
unlike much lower subanesthetic doses, and in this way corresponds to the 
anesthetic states produced by isoflurane, sevoflurane, and urethane, which also 
reduced MAPK phosphorylation (I). 
MAPK phosphorylation is increased in vitro in primary cultured neurons 
by rapid-acting antidepressants and is thought to be dependent on both AMPA 
and TrkB receptors (Lepack et al., 2016). According to Lepack et al., this in-
crease in MAPK phosphorylation was not evident with traditional antidepres-
sants, which suggests that it might be a particular property of rapid-acting 
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treatments at least in primary cultures. Other studies have also connected neu-
rotrophic signaling via the BDNF receptor TrkB with the antidepressant-like 
behavioral effects of both traditional and rapid-acting antidepressants (Saare-
lainen et al., 2003; Sun et al., 2016). Chronic treatment with traditional anti-
depressants is known to increase the synthesis of BDNF (Nibuya et al., 1995), 
which has been proposed to act through its cognate receptor TrkB to promote 
plasticity (Karpova et al., 2011; Vetencourt et al., 2008). However, antidepres-
sants can also transactivate TrkB in the absence of BDNF (Rantamäki et al., 
2011), and similar transactivation may occur with isoflurane, sevoflurane, and 
halothane (Antila et al., 2017). 
One of the downstream targets of neurotrophic signaling is the mTor path-
way, a key regulator of protein synthesis and cellular metabolism (Magnuson 
et al., 2012), which has been proposed to underlie some of the changes in syn-
aptic proteins and spine formation following ketamine administration in ro-
dents (Li et al., 2010). Activators upstream of mTOR are protein kinase B (i.e. 
Akt) and MAPK (Inoki et al., 2006). Furthermore, the activation of GSK3β 
inhibits mTor activation. Downstream of mTor is the ribosomal protein S6 ki-
nase beta-1, also known as p70S6K (Magnuson et al., 2012), a serine-threonine 
kinase that is phosphorylated and activated consequently via mTOR activity 
by ketamine in the prefrontal cortex of rats (Li et al., 2010). The activation of 
p70S6K further targets the S6 ribosomal protein, which induces protein syn-
thesis at the ribosome (Magnuson et al., 2012). While this study did not reveal 
phosphorylation changes on p70S6K, we investigated these in another study 
and found increased phosphorylation after isoflurane anesthesia in the hippo-
campus and mPFC of mice (Antila et al., 2017).
6.2 Nitrous oxide regulates neuronal signaling  
  events implicated in rapid antidepressant effects 
The intriguing clinical report by Nagele et al. (2015) led us to investigate 
whether nitrous oxide, a gaseous anesthetic, would produce similar molecu-
lar alterations to those previously witnessed after ketamine and isoflurane. We 
were surprised to find that an acute 30 min nitrous oxide (50% N2O/O2) treat-
ment had little impact on the phosphorylation levels of TrkBY816, p70S6kT421/S424, 
and GSK3βS9 measured from mPFC samples (II). It did, however, increase the 
phosphorylation of p44/42-MAPKT202/Y204, suggesting increased cortical excit-
ability taking place during N2O administration. Indeed, nitrous oxide readily 
regulated the expression of multiple IEGs (Arc, Bdnf, Bdnf exon IV, cFos, EGR2, 
Homer1a, MKP1, Synapsin 1, and Zif268). In further support of this idea, a pre-
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vious study has suggested that the cerebral metabolic rate (CMR) is increased 
during nitrous oxide anesthesia in goats (Pelligrino et al., 1984). Increases in 
cerebral blood flow (CBF) with nitrous oxide inhalation have also been mea-
sured in humans (Deutsch & Samra, 1990; Field et al., 1993). 
We also conducted EEG measurements during and after nitrous oxide 
treatment, which revealed that once the gas administration ceased, mice exhib-
ited increased slow EEG oscillations – a phenomenon also reported in human 
trials (Foster & Liley, 2011; Henrie et al., 1961; Williams et al., 1984). Since we 
had previously seen phosphorylation changes in GSK3βS9 and p44/42-MAP-
KT202/Y204 after high doses of various anesthetics known to silence EEG activity 
(I), we investigated whether these molecular alterations are present during the 
increased slow EEG activity following the cessation of nitrous oxide admin-
istration. Indeed, nitrous oxide increased TrkB, GSK3β, and p70S6K phos-
phorylation in mPFC samples collected after the cessation of gas flow (II). 
Moreover, a subanesthetic dose of ketamine (10 mg/kg, i.p) produced a similar 
homeostatic rebound of slow EEG oscillations after the acute pharmacolog-
ical effects of the drug were dissipated. We continued to test the connection 
between excitatory activity, subsequent EEG slowing, and the associated mo-
lecular changes by utilizing flurothyl to trigger generalized seizures. These sei-
zures were followed by prominent post-ictal increases in slow EEG activity, 
and when mPFC samples were collected during this state, significant increases 
in the phosphorylation of TrkB, GSK3β, and p70S6K were noted. Phosphory-
lation of TrkB, GSK3β, and p70S6K, however, remain unaltered immediately 
following the seizure when slow oscillations had not yet emerged (Rosenholm 
M, unpublished). Thus, we hypothesized that ketamine, nitrous oxide, and 
flurothyl drive excitatory activity in the cortex, to which the brain responds 
with the homeostatic emergence of rebound slow EEG activity. We also hy-
pothesized that during this process, TrkB signaling becomes activated. 
Since nitrous oxide produced an upregulation of Bdnf expression (II), the 
synthesis of BDNF and its actions through TrkB receptors may be involved in 
the subsequent emergence of slow EEG activity. Interestingly, BDNF injected 
intracerebroventricularly in rats and rabbits has been shown to produce in-
creases of time spent in non-rapid eye movement (NREM) sleep (Kushikata et 
al., 1999), and cortical unilateral microinjections of BDNF have been shown 
to increase SWA in the injected hemisphere during subsequent sleep periods. 
On the other hand, TrkB receptor inhibitor K252a produces a decrease in SWA 
(Faraguna et al., 2008). In addition, BDNF has been demonstrated to modu-
late baseline and homeostatic regulation of REM sleep (Garner et al., 2018). 
These findings are most interesting since BDNF is also upregulated by ECT, 
and sleep disturbances are a key feature of depression (Breslau et al., 1996; 
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Germain et al., 2004). However, since we did not investigate acute changes in 
BDNF levels in our study or elucidate whether TrkB activation was dependent 
on BDNF, these ideas remain speculative. The results of these studies and ef-
fects of rapid-acting antidepressants on rebound SWA should be investigated 
in Bdnf deficient animals.
BDNF signaling via its cognate receptor TrkB is thought to be dependent 
on neuronal activity and to control activity-dependent plasticity (Ernfors et al., 
1991; Hall et al., 2000; Poo, 2001). However, the receptor may also be transac-
tivated independently of BDNF (Rantamäki et al., 2011). The phosphorylation 
of TrkB, particularly during sedative states, accompanied by increased slow 
EEG activity, may thus suggest activity- and BDNF-independent mechanisms. 
This transactivation of TrkB receptors has been proposed to also occur during 
isoflurane anesthesia (Antila et al., 2017). In our study, however, we did not 
further elucidate the molecular mechanisms behind TrkB activation. It has 
been suggested that BDNF-induced activation of TrkB phosphorylates Y515 
residue acting as the Shc binding site (Guo et al., 2014; Segal et al., 1996) could 
be possibly used to distinguish between BDNF-dependent and independent 
activation, since this site is not phosphorylated by isoflurane (Antila et al., 
2017). A better strategy would be to utilize forebrain-specific Bdnf knockout 
mice and test whether TrkB phosphorylation events take place in these ani-
mals in response to the treatments. It also remains to be investigated whether 
TrkB activation during increased slow EEG oscillations recruits other canon-
ical downstream pathways and if the phosphorylation of p70S6K and GSK3β 
are dependent on TrkB activation.
These effects of anesthetics may be dependent on direct receptor-medi-
ated mechanisms, but on the other hand, these changes could also occur in 
response to more global changes in neuronal metabolism and network activity. 
Notably, many previous studies have reported abnormalities in the regulation 
of energy metabolism in association with MDD, including deficits in cerebral 
blood flow (Bench et al., 1993; Schlegel et al., 1989), glucose metabolism (Bax-
ter et al., 1989; Li et al., 2015), and mitochondrial function (Allen et al., 2018). 
For example, a high resolution positron emission tomography study looking at 
the effects of ECT on CBF reported an increase during seizure activity in the 
basal ganglia, brainstem, diencephalon, amygdala, and vermis as well as in the 
frontal, temporal, and parietal cortices, while a decrease was evident during 
the post-ictal period in the anterior cingulate and frontal cortex (Takano et al., 
2007). Both the anterior cingulate and the frontal cortex have been implicated 
in the pathophysiology of depression (Drevets, 2000), and the reduction of 
blood flow to these areas have been associated with positive clinical responses 
(Nobler et al., 1994). These results of decreased postictal CBF in the cortex are 
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also in line with the vast literature of EEG studies related to postictal anterior 
slowing after ECT (Fosse & Read, 2013) and our findings of EEG slowing 
after flurothyl-induced seizures. However, further studies are needed to fully 
understand the similarities and differences between the postictal state and the 
rebound increase of slow EEG oscillations after nitrous oxide and ketamine 
administration.
6.3  Medetomidine increases TrkB-GSK3β  
  signaling, but does not produce  
  antidepressant-like behavioral effects
We pursued the connection between slow EEG activity and the observed mo-
lecular signaling mechanisms further using medetomidine, a sedative drug with 
a completely different pharmacological mode of action than nitrous oxide and 
ketamine (II). Unlike NMDA antagonists, medetomidine activates α2-adrener-
gic autoreceptors and decreases neurotransmitter release (Sinclair, 2003). We 
demonstrated that medetomidine produces a rapid increase in slow frequency 
power after an IP injection in mice – similar to that seen in humans during dex-
medetomidine sedation (Sleigh et al., 2018; Xi et al., 2018). Moreover, to vali-
date the claim of medetomidine not producing cortical excitation, we demon-
strated that medetomidine does not induce changes in the expression of IEGs 
in the mPFC two hours after drug administration. Most importantly, when 
brain samples were collected 30 min after the injection of medetomidine, during 
the medetomidine-induced slow EEG activity, we saw robust increases in TrkB, 
GSK3β, and p70S6K phosphorylation, while p44/42-MAPK phosphorylation 
was downregulated. These results suggest that these molecular alterations are 
either driven by the brain state characterized by increased slow EEG activity or 
coincide with it.
We continued to investigate whether the direct facilitation (i.e. not rebound 
emergence) of slow EEG oscillations and the accompanying phosphorylation 
alterations (but lack of excitatory markers) induced by medetomidine produces 
antidepressant-like responses in the learned helplessness (LH) model of depres-
sion (II). In our experiments, untreated mice were first exposed to inescapable 
mild foot shocks during two pre-test days, which effectively rendered the ani-
mals helpless – that is, they no longer tried to escape the unpleasant stimuli. On 
the third day, the animals were tested again with the possibility of escaping the 
shocks by crossing into another chamber. After this, saline, ketamine or mede-
tomidine was administered, and the animals were retested again 24 hours later 
to quantify changes in their avoidance behavior. Notably, medetomidine failed 
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to elicit any antidepressant-like effects in the learned helplessness model, but 
subanesthetic ketamine effectively ameliorated the avoidance deficit. 
Previous studies have demonstrated that both ketamine (Autry et al., 2011; 
Beurel et al., 2011; Li et al., 2010; Zanos et al., 2016) and ECS (Biedermann et 
al., 2012; Sartorius et al., 2003) produce antidepressant-like effects in the LH. 
However, it is important to keep in mind that all behavioral tests in rodents have 
limitations. Despite the possibility that the behavioral results might not be mea-
suring antidepressant effects as such, these findings provide novel evidence of 
medetomidine-induced phosphorylation of TrkB, GSK3β, and p70S6K without 
promoting antidepressant-like behavioral outcomes (II). Besides antidepres-
sant drugs and anesthetics, the acetylcholinesterase inhibitors donepezil and 
galantamine have also been shown to activate TrkB in the mouse hippocampus, 
while not affecting MAPK phosphorylation (Autio et al., 2011). Since drugs like 
medetomidine and donepezil are not known to have antidepressant effects in 
humans, TrkB activation by itself does not seem to be sufficient for clinically ef-
fective therapeutics. It may also be the case that the phosphorylation alterations 
we see during slow EEG activity are not relevant for treating depression per se, 
but may hold other neurobiological significance, for example in the cascade of 
events that leads to putative alterations in neuronal network function.
One of the clearest differences between medetomidine and ketamine is 
their differing ability to affect cortical excitability. Above all, clinical evidence 
supports the excitatory activity of nitrous oxide and ketamine and the lack of 
excitatory activity for pharmacological sedatives. For example, nitrous oxide 
has been reported to increase global CBF via the augmentation of blood flow 
in frontal cortical areas, but increases have also been noted in the basal ganglia, 
insula, and thalamic regions (Reinstrup et al., 1994). In a PET imaging study, 
nitrous oxide on was found to have a minor but not statistically significant ef-
fect on global CMR (Reinstrup et al., 2008). However, the inhalation of nitrous 
oxide was shown to change the regional distribution of CMR, with increases in 
the thalamus and the basal ganglia. Moreover, nitrous oxide may particularly 
increase metabolism in the limbic system (Reinstrup et al., 2008, 1994), which is 
also supported by experiments using depth-electrode measurements of the lim-
bic and thalamic regions in epileptic patients who displayed increased activity 
after ketamine and nitrous oxide administration (Ferrer-Allado et al., 1973). On 
the other hand, sedative drugs like midazolam that lack any obvious antide-
pressant effects seem to reduce regional CBF in regions including the prefrontal 
cortex and thalamus (Veselis et al., 1997). Furthermore, a clinical study com-
paring dexmedetomidine, propofol, sevoflurane, and S-ketamine on regional 
CMR using PET imaging reported that only S-ketamine did not reduce CMR 
(Laaksonen et al., 2018).
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6.4  Two phases of rapid antidepressant action:  
  a hypothesis
Based on our findings, we formulated a hypothesis of the two-phased action 
of rapid-acting antidepressants in the brain (Figure 15). According to our hy-
pothesis, the first phase of action takes place during the acute pharmacological 
effects – that is, during N2O inhalation or during ongoing ketamine infusion, 
when the cerebral cortex is directly under the influence of said rapid-acting 
antidepressant. The acute drug-induced excitation may be reflected by EEG 
changes, such as increased gamma power during ketamine administration, or 
measurable as molecular changes (e.g. increased IEG expression and increased 
phosphorylation of MAPK). The excitatory phase then results in the emer-
gence of homeostatic slow EEG oscillations in the second phase, when the 
drug has been cleared, metabolized, or excreted from the body. We speculate 
that this increase in slow EEG activity is an inherent property of neuronal 
networks responding to the preceding excitation, and during this state, the 
phosphorylation alterations in neurotrophic pathways (e.g. increases in TrkB, 
GSK3β, and p70S6K and decreases in p44/42-MAPK phosphorylation) also 
become activated via endogenous mechanisms. However, the direct induction 
of these phosphorylation alterations by triggering a sedative brain state or in-
creasing slow wave activity without the preceding excitatory drive may not be 
enough to achieve therapeutic effects (i.e. medetomidine).
Since our hypothesis suggests cortical excitation and the subsequent reg-
ulation of molecular alterations during slow EEG oscillations as the driving 
forces behind the therapeutic effects of rapid-acting treatments, one must ask 
how these fit into the putative rapid-acting antidepressant effects of general 
anesthetics such as isoflurane or propofol. Notably, it has been suggested that 
general anesthetics do not cause a global suppression of neuronal activity, but 
result in more differential effects on cortico-cortical and thalamo-cortical net-
works (Alkire et al., 2008; Liu et al., 2013; Mashour & Alkire, 2013). Moreover, 
general anesthetics may produce transient excitatory effects both during the 
induction of anesthesia and during emergence from anesthesia, which are of-
ten called “emergence phenomena” (Cascella et al., 2018). These effects appear 
to take place particularly during periods when the concentration of the drug 
being administered has not yet reached anesthetic levels or has been reduced 
from anesthetic concentrations (Kuizenga et al., 1998, 2001). The molecular 
alterations coinciding with these phases of anesthesia remain to be investigated 
in this context.
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Our results bring up a further important aspect to consider, which is relat-
ed to the pharmacokinetic properties of neuropharmacological drugs. Ket-
amine, for instance, has a relatively rapid rate of metabolism, which makes 
the acute pharmacological effects of the drug brief. For example, in the study 
of Li et al. (2010), ketamine (10 mg/kg, IP) administered to rats produced a 
rapid increase in the phosphorylation of p44/42-MAPK and Akt in the PFC 
that was visible both 30 minutes and 1 hour after the injection, but not at sub-
Figure 15. Hypothesis of the two phases of rapid-acting antidepressant action. The 
first phase (left side of the dashed line) occurs during the acute pharmacological chal-
lenge and is characterized by increases in cortical excitability and synaptic potentiation. 
It is also marked by changes in the transcription of immediate-early genes and increased 
MAPK phosphorylation. The second phase (right side of the dashed line) occurs when 
the rapid-acting antidepressant is no longer present, and is characterized by an increase 
in the homeostatic regulation of slow EEG activity coinciding with increased phosphor-
ylation of TrkB, GSK3β, and p70S6K (downstream of mTOR), while MAPK phosphor-
ylation is reduced. These alterations may, for example, coincide with the consolidation 
of activity-driven changes or initiate synaptic downscaling, ultimately resulting in the 
reconfiguration of network activity. Increased phosphorylation is marked by (+) and 
decreased phosphorylation by (-).
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sequent time points. This time course seems to readily follow the half-life of 
ketamine. Since post-translational modifications like the phosphorylation of 
proteins can be regulated in a scale of minutes, the precise time point of the 
collection of samples may have significant influence over the state of phos-
phorylation events.  This is best exemplified by our results regarding N2O, 
which is essentially removed from the body almost instantaneously once the 
gas flow is ceased. In the experiments with N2O, a brief change in the sample 
collection time reflected surprisingly different results. 
Hypothetically, the rapid clearance of ketamine may also be important 
for its therapeutic effects, since many other NMDAR antagonists have failed 
to demonstrate such robust antidepressant effects. Memantine, for example, 
has a half-life that is between 60 and 100 hours in humans (Matsunaga et 
al., 2018), and has been given to patients daily in clinical trials studying its 
antidepressant effects (Lenze et al., 2012; Zarate, Singh, Quiroz, et al., 2006). 
Besides the differences in the pharmacology of ketamine and memantine, 
the differences in the pharmacokinetic properties and dosing pattern also 
differentiate these treatments. According to our hypothesis, the rapid clear-
ance and “pulse-like” administration of ketamine allows the drug to briefly 
excite the cortex and then give way to the subsequent phases of homeostatic 
realignment. Contrary to ketamine, once memantine is administered, it acts 
in the brain for days. If stable concentrations of the drug are reached through 
chronic daily administration, the homeostatic response of the brain will be 
to readjust to maintain that state. Indeed, the relatively brief duration of ac-
tion is a shared property of ketamine, N2O, isoflurane, propofol, and ECT. 
Rapid-acting antidepressants are also pharmacologically rapid-acting. Most 
importantly, the effects of rapid-acting antidepressants seem to become most 
evident when the drug has already been cleared from the body, suggesting 
that lasting changes took place during administration. Furthermore, the ef-
fects may last from days to weeks after just one single treatment, suggesting 
that the rapid changes initiated by the drug are consolidated to some degree. 
These properties share similarities with what is known about the mechanisms 
of memory, a property of neuronal networks that illustrates similar rapidly 
induced but long-lasting changes.
Physiologically, a strong stimulus may trigger the formation of memo-
ries, recapitulated by changes in synaptic strength via mechanisms such as 
protein phosphorylation and increases in synaptic function via LTP (Bear, 
1997; Nicoll, 2017). Without subsequent consolidation, the synaptic strengths 
decay back and the encoded information is lost. Short-term memories have 
been proposed to transform into long-term memories through a process 
called synaptic tagging (Frey & Morris, 1997). In synaptic tagging, a stim-
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ulus establishes molecular “tags” in specific synapses that can then become 
further potentiated (i.e. L-LTP) by later associating with newly synthesized 
plasticity-related proteins. In L-LTP, changes in postsynaptic gene transcrip-
tion are thought to be triggered (Pittenger & Kandel, 1998). Kinases already 
triggered during E-LTP are thought to contribute to L-LTP, such as MAPK 
(Thomas & Huganir, 2004), CaMKII (Ma et al., 2014), Akt (Pen et al., 2016), 
PI3K (Asrar et al., 2009) and PKC subtypes (Jalil et al., 2015), many of which 
are also putative downstream (or upstream) targets of TrkB signaling. These 
pathways then further contribute to the phosphorylation of other targets, 
such as transcription factors like CREB (Barco et al., 2002), which further 
leads to changes in protein synthesis by key regulators like mTOR (Hay & 
Sonenberg, 2004; Tang et al., 2002). De novo protein synthesis is suggested to 
be required for the maintenance of induced LTP, which is relevant to the for-
mation of lasting memories (Bekinschtein et al., 2007; Goelet et al., 1986) and 
to the behavioral effects of ketamine (Girgenti et al., 2017; N. Li et al., 2010). 
It is plausible that major differences in the extent, duration, and selec-
tivity of the excitatory activity produced by rapid antidepressant treatments 
may also determine their functional consequences. While flurothyl (and 
ECT)-induced seizures are a very pronounced form of global excitatory ac-
tivity, ketamine and nitrous oxide seem to drive this excitation in a subtler 
way. It may be that during the excitatory phase, IEGs are produced by the 
activation of, for example, particular thalamocortical networks, which leads 
to their translation during the subsequent period of slow EEG activity, and 
ultimately leading to sustainable functional changes. This way, network ac-
tivity, for example, in the form of synaptic tagging (Frey & Morris, 1997) or 
inverse synaptic tagging via mechanisms implicating Arc (Okuno, Akashi, 
Ishii, Yagishita-Kyo, et al., 2012), may be consolidated in subsequent phases. 
Moreover, excitation during the acute pharmacological effects may drive ac-
tivity into specific or preferential networks, depending on the properties of 
the treatment. Thus different drugs may have different effects on a network 
level. This could explain why ECT has a wide profile of deleterious cognitive 
effects while isoflurane anesthesia or subanesthetic ketamine are less prone 
to producing negative cognitive effects. Since in ECT the electrical current 
led to the brain is in no way selective as to which neuronal populations are 
activated, this activity and remodeling of the networks may incite not only 
therapeutic effects but also changes that are detrimental to memory and cog-
nitive functions.
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6.5 The putative role of slow EEG activity in rapid  
  antidepressant mechanisms 
Our results provide evidence of a translationally relevant electrophysiologi-
cal parameter – slow EEG activity – that correlates with specific phosphory-
lation alterations in neurotrophic pathways. The increase of slow EEG activi-
ty is particularly interesting, since similar increases in delta frequency power 
are physiologically evident during stages of non-rem (NREM) sleep (Davis 
et al., 2011). The SyNApTIC hOMEOSTASIS hypOThESIS (SHY) proposed by 
gIulIO TONONI and ChIARA CIREllI (2003) states that SWA, which increases 
as a function of previous wakefulness and decreases over the course of sleep, 
drives molecular and structural changes in neuronal networks during NREM 
sleep. While the task of connecting sleep- and waking-related molecular and 
cellular changes to behavioral and cognitive effects is unarguably complex, 
SHY provides an interesting framework to apply to the effects of rapid-acting 
antidepressants. 
The SHY proposes that a net increase in the strength of neuronal connec-
tions takes place during waking, while a net decrease takes place during sleep 
(Tononi & Cirelli, 2014). Activity-induced changes during waking are encod-
ed into long-lasting changes in the strength, number, and wiring of neuronal 
connections, driven by cellular signaling cascades. Among these cascades are 
activity- and plasticity-related genes such as Bdnf and Arc and the phosphory-
lation of transcription factors such as CREB. The expression of these LTP-re-
lated molecular markers is, however, markedly reduced during sleep (Cirelli & 
Tononi, 2000). While synaptic strengthening takes place during wakefulness 
and learning, a balancing act is required to prevent excess potentiation. Ac-
cording to SHY, this balance is achieved by the consecutive potentiation and 
depotentiation taking place along the 24-hour sleep/wake cycle in humans. 
During waking hours, our brains are active, and we connect to the external 
environment through our senses. This provides an optimal time for interacting 
and learning. During sleep, however, our brains become disconnected from 
the external world, allowing the restoration of synaptic weights to take place. 
This state is particularly ideal for systematic synaptic renormalization because 
it is not influenced by ongoing sensory experience and activity (Tononi & 
Cirelli, 2019). Notably, recent ultrastructural evidence from experiments us-
ing three-dimensional electron microscopy in mice demonstrated a decrease 
in the axon-spine interface after sleep compared with wakefulness (de Vivo et 
al., 2017). Moreover, other studies have reported decreases in cortical AMPAR 
expression after sleep (Diering et al., 2017; Vyazovskiy et al., 2008).  
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The state of wakefulness is inherently accompanied by LTP-like changes in the 
brain and the buildup of synaptic potentiation, and is supported by increas-
es in the synaptic density and neuronal complexity of animals subjected to 
interventions like an enriched environment or whisker stimulation (Knott et 
al., 2002; Kolb et al., 1998; May-Britt et al., 1998; Tononi & Cirelli, 2014). The 
SHY postulates that this potentiation is connected to the homeostatic increase 
of SWA during subsequent periods of sleep, and is perhaps mediated by the 
buildup of LTP-related molecules. While the mechanisms of SWA increase are 
still unclear, the increase of SWA after extended wakefulness does not seem to 
be explained only by neuronal fatigue after sustained firing (Rodriguez et al., 
2016). The SHY proposes that the amount of SWA is a direct reflection of the 
strength of corticocortical synapses and their potentiation (Tononi & Cirelli, 
2003).  
In NREM sleep, cortical and thalamic neurons oscillate between up and 
down states, characterized respectively by the tendency to fire or not (To-
noni & Cirelli, 2019). This rhythmic activity can be measured as slow waves 
in cortical EEG and has been proposed to be important for sleep-dependent 
down-selection, along with electrical activity like hippocampal sharp waves/
ripples (Norimoto et al., 2018). Accumulating evidence suggests that sleep-de-
pendent renormalization of synaptic strength spares neuronal connections that 
are most active during sleep (Tononi & Cirelli, 2019). According to SHY, a 
process must exist for selective down-selection in order for sleep to promote 
learning and memory consolidation while also permitting the refinement of 
circuitries and forgetting (Tononi & Cirelli, 2014). Such protection from syn-
aptic depression has been evaluated in computer simulations (Hashmi et al., 
2013; Nere et al., 2013) and recently gained support from an in vivo study 
where urethane anesthesia was used to reproduce the up and down states of 
NREM sleep (González-Rueda et al., 2018). In this study, conventional rules 
of spike-timing-dependent synaptic plasticity applied when presynaptic affer-
ents in the mouse barrel cortex were optogenetically stimulated during down 
states. However, stimulation during up states never led to increases in synaptic 
strength, which remained unchanged when presynaptic activation was cou-
pled with postsynaptic activity and decreased when postsynaptic activity was 
coincidental. As proposed by the work of González-Rueda et al. (2018) and 
discussed by Tononi and Cirelli (2019), since neurons rarely fire during down 
states and up states last longer than down states during sleep, these mecha-
nisms could explain the wide yet synapse-specific renormalization that is able 
to spare those connections that fire congruently. In other words, synapses ad-
equately strengthened during wakefulness and learning would be resistant to 
synaptic depression.
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Our results demonstrate the connection between increased slow EEG activity 
and the activation of neurotrophic pathways (II, III). If these bear any simi-
larity to the neurobiological mechanisms of sleep or to what SHY proposes, 
the latter phase of regulation (i.e. slow EEG activity after the acute effects) or 
the increase of slow EEG activity during subsequent nights may be related to 
the downscaling of neuronal connections. On the other hand, the first phase of 
excitation that occurs during acute treatment may activate specific patterns of 
neuronal activity, which then result in specific connections being preferential-
ly spared from synaptic downscaling. Applied to ketamine, these mechanisms 
could result in the acute potentiation of selected networks, resulting in the 
rapid onset of antidepressant action. This potentiation would then spare these 
connections in the down-selection during subsequent sleep and slow EEG ac-
tivity, effectively upkeeping the relative potentiation of these connections and 
consolidation into functionally meaningful changes that manifest as a lasting 
reduction of depressive symptoms. 
Indeed, the rapid-acting antidepressant effects of ketamine are most 
prominent 24 hours after the treatment, essentially after a night of sleep. This 
timescale suggests that endogenous mechanisms of sleep regulation may in-
deed interact with the pharmacological effects of ketamine and other putative 
rapid-acting antidepressants. Moreover, the antidepressant effects of ketamine 
typically wear off within several days or a few weeks, but can be restored by 
another dose of ketamine. Hypothetically, this loss of antidepressant effects 
could result from several consecutive periods of renormalization during sub-
sequent nights of sleep, which eventually reset the relative potentiation of spe-
cific networks if no further stimulus (i.e. ketamine treatment) is applied. No-
tably, increased SWA has been reported during the night following ketamine 
treatments, and this has been proposed to predict the therapeutic efficacy of 
the treatment (Duncan, Sarasso, et al., 2013). 
Synaptic strength is governed by the trafficking and insertion of AMPARs 
into the synaptic membrane and by their removal. Among proteins involved in 
these processes are Homer1a (Diering et al., 2017), Arc (Okuno, et al., 2012), 
GSK3β (Beurel et al., 2016), and MAPK (Zhu et al., 2002). Our results demon-
strate changes in the expression of Homer1a and Arc after N2O administration 
and the subsequent regulation of GSK3β and MAPK during increased slow 
EEG activity. Notably, Tononi and Cirelli (2019) speculate that the Ser9 phos-
phorylation of GSK3β could be involved in the mechanism of tagging synaps-
es potentiated during wakefulness and their protection from down-selection. 
Since our studies have concentrated on whole tissue lysates, it is impossible to 
further evaluate the compartmentalization of said molecular changes. In this 
regard, further studies using enriched postsynaptic densities or synaptosomal 
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preparations may provide additional insights into these mechanisms. Taken 
together, these findings, combined with the vast amount of literature pointing 
towards the role of slow EEG oscillations in the therapeutic efficacy of ECT, 
highlight the possibility that rapid antidepressant effects may be intimately 
tied to the neurobiology of sleep and memory.
6.6 Dose-dependent effects of ketamine on   
  TrkB-GSK3β signaling
In our third study, we investigated the dose-dependent effects of ketamine in 
the regulation of TrkB-GSK3β signaling. Notably, a recent study by Zanos et 
al. (2016) suggested that a metabolite of ketamine, cis-HNK, is responsible for 
ketamine’s rapid antidepressant effects. Thus, we also investigated whether it is 
ketamine or its cis-HNK metabolite that drives changes in the molecular path-
ways implicated in ketamine’s antidepressant-like effects (III). We found that 
higher doses of ketamine (100 mg/kg, IP) effectively regulated TrkB, GSK3β, 
and p70S6K phosphorylation, while subanesthetic doses (10 mg/kg, IP) did 
not. Furthermore, our EEG recordings provide further evidence for slow EEG 
oscillations coinciding with the previously mentioned phosphorylation chang-
es. High doses of ketamine capable of increasing delta frequency power also 
activate TrkB signaling. Moreover, our results demonstrate that an anesthetic 
dose of 6,6-d2-ketamine produces alterations in the previously mentioned path-
ways similar to those produced by ketamine, while cis-HNK failed to produce 
any acute effects on slow EEG activity or TrkB signaling.
These results are especially interesting in the context of preclinical and 
clinical ketamine research. Subanesthetic doses of ketamine (~0.5 mg/kg given 
over a 40-minute infusion) have been consistently used in clinical trials and 
have been reported to produce antidepressant effects. However, there is also 
active discussion in the literature about the relationship between the antide-
pressant responses and the psychoactive or dissociative symptoms elicited by 
higher but still subanesthetic doses (Lai et al., 2014; Loo et al., 2016; Lucken-
baugh et al., 2014; Niciu et al., 2018; Sos et al., 2013; Xu et al., 2016). Interest-
ingly, in a recent clinical trial, lower doses (0.1 and 0.2 mg/kg) were not found 
to produce clinically meaningful antidepressant effects, while higher doses (0.5 
and 1.0 mg/kg) were effective (Fava et al., 2018). In the preclinical context, a 
dose of 10 mg/kg has been most commonly used in studies demonstrating an-
tidepressant-like effects in rodents (Li et al., 2010; Zanos et al., 2016). However, 
studies thoroughly validating the basis for the selection of this dose and its 
translational relevance are lacking. 
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A recently published study implicates BDNF and mTOR signaling in the an-
tidepressant-like effects of HNK (Fukumoto et al., 2018). The authors report 
that antidepressant actions of (2R,6R)-HNK can be blocked in mice using an 
antibody against BDNF. Moreover, the blockade of L-type VGCCs, TrkB, or 
mTOR signaling result in abolished antidepressant-like behavioral effects, sug-
gesting activity-dependent BDNF release to play a key role in the effects of 
HNK. Notably, 30 mg/kg of (2R,6R)-HNK was required to produce effects 
equivalent to those of 10 mg/kg of ketamine in behavioral assays and in the 
phosphorylation of mTOR. Our study used a relatively high dose of 20 mg/kg 
of cis-HNK, and we could not detect any statistically significant differences in 
p70S6K phosphorylation, a target downstream of mTOR activation. While a 
higher dose of HNK may indeed produce similar phosphorylation alterations 
as ketamine, 10 mg/kg of ketamine does not metabolize into 30 mg/kg of 
(2R,6R)-HNK or to 20 mg/kg of cis-HNK. This discrepancy of using massive 
doses of HNK compared to small doses of ketamine does not support the idea 
that ketamine’s effects are solely mediated by HNK. It is plausible that ket-
amine and the part metabolized to HNK may interact to produce additive mo-
lecular changes. However, in our study, we compared the effects of equivalent 
doses of ketamine and 6,6-d2-ketamine and found their effects to be essentially 
similar. Furthermore, while Fukumoto et al. (2018) reported increased mTOR 
phosphorylation after 10 mg/kg of ketamine, we did not see any changes in 
the phosphorylation of p70S6K with the same dose. The discrepancy between 
these results remains to be clarified, but may be due to differences in sample 
processing, for example, the use of raw lysates versus synaptosomal fractions.
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6.7 Translational remarks
A severe translational gap exists between preclinical and clinical experiments 
in the study of rapid-acting antidepressant effects, with several preclinically 
promising drug candidates having failed in clinical trials. One possible way 
to achieve better relevance for preclinical results would be to comprehensively 
compare the effects of rapid-acting antidepressants like ketamine on transla-
tionally relevant electrophysiological parameters of brain activity. However, 
several limitations are involved in techniques such as EEG and their interpre-
tations for mice versus humans. Comprehensive EEG recordings combined 
with the study of brain drug pharmacokinetics in rodents would still provide 
important information on adjusting treatments to further match the clinical 
setting. Notably, ketamine is most often administered as IP or SC injections to 
rodents. Almost all clinical trials have employed an IV infusion. This discrep-
ancy likely exists for the convenience of the researchers and due to the difficul-
ty of IV administration in rodents. However, several methods such as infusion 
minipumps could be considered to combat these obstacles. From this perspec-
tive, nitrous oxide also provides a more promising translational option to study 
the effects of putative fast-acting antidepressants in rodents, since its adminis-
tration and pharmacokinetic properties are relatively similar in humans.
Behavioral assays have dominated the field of depression research since the 
very first tests were developed along with the discovery of monoaminergic anti-
depressants. Some of these tests, such as FST, sometimes demonstrate a rapid 
amelioration of depressive symptoms after antidepressant administration. No-
tably, humans typically do not experience the rapid alleviation of depressive 
symptoms with traditional antidepressants, raising questions about the nature 
of these responses in rodents. Many animal models also use long-term mild 
stress to produce depression-like phenotypes, however, the depressive behav-
ior is typically ameliorated by the removal of the stressor (Grippo et al., 2003). 
Major depressive disorder, in contrast, often persists when external causes are 
improved (Belmaker & Agam, 2008). While these animal models might be use-
ful in finding new drugs that act on monoaminergic mechanisms, they might 
not be as valuable in the discovery of novel antidepressants with lesser-known 
mechanisms of action. Moreover, the ability of these models to distinguish 
rapid antidepressant effects requires further study. Since our understanding of 
the pathogenesis of depression and the mechanisms of antidepressants remains 
incomplete, we are also lacking in animal models that effectively represent hu-
man depression (Nestler et al., 2002).
Instead of relying heavily on animal models, our studies mostly ap-
proached rapid-acting antidepressants from the perspective of their neuro-
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pharmacological and neurophysiological features. This provided the opportu-
nity to find shared pharmacological targets and features of various drugs that 
have clinically relevant fast-acting antidepressant effects. A possible limitation 
of our work is the use of naïve animals, which requires the presupposition that 
naïve animals will display relevant biochemical and physiological responses 
when treated with drugs that have clinical relevance in treating depression. As 
demonstrated by the work in this thesis, this line of approach has great poten-
tial for future discoveries. For example, combining complementary methods 
like phosphoproteomics, metabolomics, and RNA sequencing with transla-
tionally relevant in vivo imaging or electrophysiological measurements may 
give further insights into common targets of rapid-acting treatments.
Our results highlight decades-old research on the mechanisms of ECT and 
raise further important questions about the connection between physiological 
brain states and the molecular mechanisms driving the rapid-acting antidepres-
sant effects of ketamine. If the mechanisms of action of rapid-acting antide-
pressants are related to putative intrinsic neurobiological mechanisms such as 
the modulation of network plasticity during SWA, several considerations may 
be important for future research. Most importantly, in clinical practice, suban-
esthetic ketamine and ECT are most often delivered during the early morning 
or early afternoon (C. Zarate & K. Järventausta, personal communications, 
23.11.2018). In preclinical research, treatments are often given during the day-
time, but since most rodent species (mice and rats) are nocturnal animals, the 
treatments take place during their inactive period. While the contrast between 
periods of activity and wakefulness are not as clearly defined in rodents as in 
humans, rodents are clearly much more active during the night. Pharmacologi-
cal and behavioral tests conducted during the inactive period of animals, when 
sleep pressure is high, may have severe confounding effects for molecular and 
behavioral tests. This discrepancy between basic and clinical research may also 
contribute to why so many preclinically effective treatments of depression fail 
in clinical trials. Moreover, since human cortical excitability is also regulated in 
a circadian manner (Ly et al., 2016), understanding its implications for central 
nervous system disorders may provide ways to further advance human thera-
peutics.
Emerging evidence of the rapid antidepressant effects of psychedelic drugs 
may be ultimately important for unraveling the neurobiological mechanisms 
of ketamine as well. For example, psilocybin has also been suggested to pro-
duce changes in spontaneous cortical excitability (Kometer et al., 2013) and 
to increase global cerebral metabolic rate of glucose utilization (CMRglu), with 
particular changes in the prefrontal cortex, associated limbic areas, and thal-
amus (Vollenweider, Leenders, Scharfetter, Maguire, et al., 1997). Essentially 
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similar increases in CMRglu have been noted in patients receiving psilocybin 
and ketamine, and this has been proposed to support the idea of converging 
mechanism behind these different drugs (Vollenweider, Leenders, Scharfetter, 
Antonini, et al., 1997; Vollenweider & Kometer, 2010). Indeed, several studies 
have demonstrated that activation of the 5HT2A receptor increases excitato-
ry activity in the PFC (Aghajanian & Marek, 1999; Beique et al., 2007; Puig, 
2003). Moreover, psychedelic drugs have also been shown to increase cortical 
glutamate release in rodents (Muschamp et al., 2004; Scruggs et al., 2003), 
similar to subanesthetic ketamine (Chowdhury et al., 2017; Moghaddam et 
al., 1997). Thus, it is tempting to speculate that psychedelics may also evoke 
similar molecular alterations after their acute effects.
To further advance the mechanistic knowledge of rapid-acting antidepres-
sant treatments, it is also worth considering the psychological dimensions of 
using psychotropic drugs as treatments. Biochemistry aside, the dissociative 
states produced by ketamine and N2O bear some resemblance to the psyche-
delic states induced by drugs like psilocybin. Both ketamine and psychedelics 
have been suggested to have positive psychological effects for depression and 
anxiety in patients that are receiving end-of-life care (Gasser et al., 2015; Grif-
fiths et al., 2016; Grob et al., 2011; Iglewicz et al., 2015; Sexton et al., 2018; 
Stefanczyk-Sapieha et al., 2008; Zanicotti et al., 2013). The subjective psycho-
logical experience triggered by potent psychotropic drugs has not received 
much attention in relation to the effects of anesthetic drugs, though it is one of 
the key interests in the study of psychedelic drugs. The role of “set and setting”, 
representing the psychological state and the environment in which psychedelic 
therapy takes place, has been given special attention in modern clinical stud-
ies of psychedelic drugs (Carhart-Harris et al., 2018; Johnson et al., 2008). If 
rapid-acting antidepressant effects are related to the modulation of neuronal 
plasticity and memory formation, the role of well-designed psychotherapy may 
be crucial in supporting their therapeutic effects. Indeed, accumulating evi-
dence suggests that traditional antidepressants may work better in a favorable 
environment, while a stressful environment promotes worse outcomes (Alboni 
et al., 2017; Branchi et al., 2013; Chiarotti et al., 2017; Viglione et al., 2019). It 
remains to be investigated whether psychological and environmental factors 




In this thesis, we examined the phosphoproteomic effects of brief isoflurane 
anesthesia in the mouse hippocampus and studied several molecular and 
electrophysiological changes induced by fast-acting antidepressants. The 
phosphoproteomic study demonstrates that isoflurane produces broad al-
terations in the hippocampal phosphoproteome, and that several molecular 
alterations are similarly regulated by anesthetic drugs other than isoflurane. 
Most importantly, our results highlight decades old research implicating the 
association of post-ictal slow EEG activity with the therapeutic effects of ECT 
and demonstrate that rapid-acting antidepressant treatments like nitrous ox-
ide and ketamine may share similar features of cortical excitation and inhi-
bition. Moreover, we demonstrate that nitrous oxide regulates the activity of 
TrkB, GSK3β, p70S6K, and MAPK differentially during acute drug exposure 
and the subsequent withdrawal, and that ketamine dose-dependently regu-
lates these signaling pathways without the direct influence of its metabolite 
HNK. Based on these studies, we formulated a hypothesis of the two phases 
of rapid antidepressant action and highlighted the intriguing association of 
slow EEG activity and the activation of signaling pathways implicated in rapid 
antidepressant effects, which may be related to the complex neurobiological 
mechanisms of sleep and memory. Further studies will be instrumental in un-
derstanding the functional significance of the molecular alterations associated 
with the described phenomena.
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The main conclusions are:
I  brief isoflurane anesthesia produces prominent phosphoproteomic  
 changes in the mouse hippocampus;
II  anesthetic/sedative doses of isoflurane, sevoflurane, ketamine,   
 and urethane produce similar phosphorylation alterations on GSK3β,  
 MAP2, and p44/42-MAPK;
III  nitrous oxide produces molecular changes indicative of cortical   
 excitation and evokes the emergence of homeostatic slow EEG   
 oscillations after the cessation of gas flow, during which TrkB-GSK3β 
 phorylation is upregulated;
IV  the emergence of post-treatment slow EEG oscillations is a shared 
 feature of nitrous oxide, subanesthetic ketamine, and flurothyl;
V  medetomidine sedation increases slow EEG oscillations and induces  
 the phosphorylation of TrkB-GSK3β, but does not produce   
 antidepressant-like effects in mice;
VI  anesthetic doses of ketamine regulate the phosphorylation of TrkB- 
 GSK3β most prominently; and
VII  increased phosphorylation of TrkB-GSK3β is not solely dependent on  
 ketamine’s non-sedative metabolite cis-hydroxynorketamine.
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